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 The human JMJD2/KDM4 family of histone lysine demethylases comprises four 
homologs: JMJD2A, JMJD2B, JMJD2C and JMJD2D. These enzymes have been implicated in a 
number of biological processes such as transcriptional activation, development and cell cycle 
control. The biological functions of these enzymes are defined by their distinct methylation site 
and state specificities. JMJD2A, JMJD2B and JMJD2C display dual specificity for trimethylated 
histone H3 Lys9 and Lys36 (H3K9me3 and H3K36me3), whereas JMJD2D is specific for 
H3K9me3. Furthermore, while most JMJD2 homologs are predominantly trimethyllysine-
specific, JMJD2D can demethylate both tri- and dimethyllysines. To enable quantitative kinetic 
studies of JMJD2 demethylases, we developed and applied a new affinity purification protocol 
that minimizes contamination by transition state metals. In order to delineate the molecular basis 
of site and state specific demethylation by the JMJD2 enzymes, we determined the first crystal 
structure of JMJD2D in the apoenzyme form and in a ternary complex with 2-OG and an 
H3K9me3 peptide. Our site specificity studies with JMJD2A and JMJD2D revealed surprising 
differences in H3K9me3 recognition by these enzymes despite the overall similarity in the 
substrate binding conformation. In addition, our docking studies with H3K36me3 and 
biochemical analysis with histone H3 hybrid peptides underscored the role of steric clashes, 
electrostatic clashes and loss of productive hydrogen bonds in occluding recognition of the 
H3K36me3 site by JMJD2D.  Our structural and biochemical analysis of the active site also 
revealed the basis for differential state specificity in the JMJD2 enzymes and highlighted the role 




structural and biochemical studies elucidate the molecular basis of the different substrate 
specificities within the JMJD2 family, which is not only key to understanding their distinct 
biological functions but will also aid in the structure-based design of selective inhibitors of 







HISTONE LYSINE DEMETHYLASES 
 
Histone Modifications and Regulation of Gene Expression 
The genomic DNA of eukaryotes is compacted into a higher-ordered structure termed 
chromatin. The fundamental unit in chromatin is the nucleosome, which is composed of basic 
proteins called histones.  Histones H2A, H2B, H3 and H4 form an octameric core around which 
approximately 146bp of DNA is wrapped (corresponding to 1.7 turns of DNA). Linker histone 
H1 and linker DNA further compact the nucleosome core particles to a 30nm fiber. The crystal 
structure of the nucleosome core particle revealed that the N-terminal tails of the histone proteins 
are exposed outside the nucleosome core (Figure 1.1) and are highly disordered [1]. Many amino 
acid residues on these tails as well as in the core are subject to a number of post-translational 
modifications such as acetylation, methylation, phosphorylation, ubiquitination, sumoylation, 
etc. Each of these modifications can ‘code’ for different functions depending on the type, 
location and context of the modification [2, 3].  One of the first well characterized modifications, 
histone lysine acetylation is associated with transcriptional activation because neutralization of 
the  amine group of lysines by acetylation dissociates DNA from histones, hence allowing 
access for the transcriptional machinery [4]. In addition, acetylated lysines recruit chromatin 
remodeling complexes such as nucleosome remodeling factor (NURF), which can bind to 
acetyllysines via bromodomain containing reader molecules such as Bromodomain PHD finger 









Figure 1.1: Crystal Structure of a Nucleosome Core Particle. Red: H2A; Green: H2B; Purple: 




acetylated regions of chromatin are often associated with poor transcribed regions. In summary, 
histone modifications can modulate the structure and dynamics of chromatin by chemically 
altering the nucleosomal interactions and recruiting a number of regulatory complexes.  
 
Biological Functions of Histone Lysine Methylation 
Lysine methylation is an abundant modification predominantly occurring on histones H3 
and H4. Unlike many histone modifications, methylation is unique because it can bring about 
varied responses based on which residue is methylated (the site) and the extent or state of 
methylation (mono-, di- or trimethylation in the case of lysines) [6, 7]. For example, methylation 
of H3K4 is often associated with transcriptional activation and methylation of H3K36 is a mark 
that is associated with the elongating form of RNA Polymerase II. In contrast, methylation of 
H3K9 and H3K27 are linked to silent genes or heterochromatin [8]. Similar to the site, the state 
of methylation can signal for diverse outcomes. For example, tri and dimethylation of H3K9 
demarcates repressed genes and heterochromatin while monomethylation of the same residue is 
seen in actively transcribed genes [9]. These differential effects are often brought about by 
different ‘reader’ molecules that are highly state and site specific, and signal for the outcome 
associated with a particular methylation mark [10]. For example, one of the readers of H3K4me3 
is the inhibitor of growth proteins ING3-5. These proteins form a part of the histone acetyl 
transferase complex and enhance transcription activation via histone acetylation [11, 12]. 
Similarly, the protein Heterochromatin Protein 1 (HP1) is highly specific for H3K9me3/me2 and 
is required for the efficient formation and maintenance of heterochromatin [13, 14]. In yeast, the 
protein Esa1p-associated factor (Eaf3) specifically recognizes H3K36me3 via its chromodomain 
and recruits the reduced potassium dependency 3 small (Rpd3S) histone deacetylase complex to
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H3K36me3 containing coding regions to hypoacetylate histones and prevent spurious 
transcriptional initiation by RNA Polymersase II [15-18]. A comprehensive list of functions 
associated with different histone methylation marks on the H3 tail is shown in Table 1.1. These 
various methylation marks are actively deposited and removed in a very specific manner by 
enzymes called Lysine Methyltransferases (KMTs) and Lysine Demethylases (KDMs), 
respectively. The biological functions of these enzymes are in part determined by their 
methylation site and state specificities.  
 
Mechanisms of Histone Lysine Demethylation 
For many years, lysine methylation was thought to be an irreversible modification owing 
to the strong nature of the C-N covalent bond. This notion was eradicated with the discovery of 
the first KDM called Lysine Specific Demethylase 1 (LSD1) [19], which catalyzes the 
demethylation of H3K4me2 and H3K4me1 [19, 20] and has been reported to demethylate non-
histone substrates such as p53 [21, 22]. These enzymes are FAD-dependent monoamine oxidases 
that oxidize the amino group of the methylated lysine (with the concomitant reduction of the 
cofactor FAD) to generate an imine intermediate. This intermediate spontaneously hydrolyzes to 
release formaldehyde. Hydrogen peroxide is also a by-product of this reaction and is formed by 
the re-oxidation of FAD by molecular oxygen. The LSD family of KDMs is highly efficient with 
turnover numbers (kcat) ranging from 2-12 min
-1
 depending on the length of the histone substrate 
used and the method by which the enzyme is assayed [20, 23-25]. Although these enzymes can 
catalyze the demethylation of mono and dimethyllysines, their need for protonated nitrogen (to 








Table 1.1: Functions of Histone H3 Lysine Methylation  
Methylation Site Methylation State Functions 
H3K4 
me3, me2 
transcriptional activation (observed in promoter 
regions), chromatin remodeling [9, 28, 29] 
me1 
transcriptional activation (observed in enhancer 
regions), chromatin remodeling [28, 29] 
H3K9 
me3, me2 
transcriptional silencing, heterochromatin formation 
[9, 13] 
me1 
transcriptional activation (observed in promoter 
regions) [9], heterochromatin assembly [30], nuclear 
assembly of newly synthesized histones [31] 
H3K27 
me3, me2 
transcriptional silencing mediated by Polycomb 
group proteins [9, 32, 33] 
me1 
transcriptional activation (observed in promoter 
regions) [9] 
H3K36 me3, me2, me1 
transcriptional elongation, prevention of spurious 
transcription by RNA Polymerase(II), regulation of 
histone deacetylation [9, 34, 35] 
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The Jumonji demethylases (JmjC) are a much larger family and are related to the cupin 
family of dioxygenses. These enzymes use Fe(II), 2-oxogluatrate (2-OG) and molecular oxygen 
to catalyze the demethylation of tri, di and monomethyllysines [26, 36-38]. The catalytic 
mechanism of JmjC enzymes is shown in Figure 1.2. In the active site, Fe(II) is first coordinated 
by a conserved His-Glu/Asp-His triad followed by the binding of 2-OG and molecular oxygen. 
This results in the formation of a highly reactive oxoferryl (IV) species and the oxidative 
decarboxylation of 2-OG to succinate. The oxoferryl (IV) species hydroxylates the substrate 
methyllysine group, and this results in the formation of an unstable carbinolamine intermediate 
that spontaneously decomposes to formaldehyde and the demethylated product.  
The JmjC family encompasses a number of subfamilies such as JHDM1 (KDM2), JMJD1 
(KDM3), JMJD2 (KDM4), JARID1, (KDM5), UTX/JMJD3 (KDM6), and PHF8/KIAA1718 
(KDM7). These enzymes have been implicated in a number of biological processes such as 
nuclear hormone signaling (JMJD2), transcriptional repression (JARID) and activation (JMJD2, 
UTX/JMJD3) and developmental signaling (UTX/JMJD3, JMJD2, PHF8) These enzyme 
families exhibit distinct methylation site and state specificities (Figure 1.3) which can largely 
determine their biological functions [26, 27, 37, 39-42]. For example, the UTX/JMJD3 sub-
family of enzymes catalyzes the removal of H3K27me3/me2, a repressive mark that is often 
enriched in developmental gene loci. It has been shown that UTX forms a part of the Mixed 
Lineage Leukemia (MLL)2/3 complex, an H3K4 methyltransferase complex that is involved in 
the upregulation of hox genes during development. The deposition of H3K4me3 (an activating 
mark) by the MLL methyltransferase in concert with the removal of the repressive mark 





















































Figure 1.3: Differential Methylation Site and State specificity in JmjC KDMs. Enzymes 




JMJD2 KDMs in Biology and Disease 
The JMJD2 family (also denoted as the KDM4 family) of demethylases is highly 
conserved from yeast to humans [36, 43-49]. The human JMJD2 family includes four homologs: 
JMJD2A (KDM4A), JMJD2B (KDM4B), JMJD2C (KDM4C) and JMJD2D (KDM4D). These 
enzymes contain an N terminal JmjN domain followed by the catalytic JmjC domain and a large 
C terminal region (Figure 1.4). In JMJD2A, JMJD2B and JMJD2C, the C terminal region is 
followed by tandem PHD and Tudor domains, while these domains are absent in JMJD2D 
(Figure 1.4). The PHD and Tudor domains are involved in the recognition of other chromatin 
modifications such as methylated lysines and arginines on histone H3 [10]. Structural studies by 
Huang et al have shown that the double Tudor domain of JMJD2A recognizes H3K4me3 and 
potentially, H4K20me3 [50]. All JMJD2 KDMs catalyze the demethylation of H3K9me3 and the 
closely related H1.4K26me3 (a repressive mark seen in linker histones) and some homologs can 
also demethylate H3K36me3 [27, 45]. These enzymes have been implicated in regulating 
numerous genomic processes, such as transcription, cell cycle progression, nuclear hormone 
signaling, embryonic stem cell self-renewal, and development [27, 41, 42, 51-57]. JMJD2A, 
JMJD2C and JMJD2D form stable complexes with the Androgen Receptor (AR) and upregulate 
the expression of downstream targets such as the Prostate Specific Antigen (PSA) and Kallikrein 
(KLK) by removing H3K9me3 at the PSA and KLK promoters [58, 59].  JMJD2C is also a target 
of the transcription factor Oct4, and is required for the maintenance of stem cell pluripotency 
[55]. JMJD2A has been implicated in regulating cell cycle progression and DNA replication 
timing by antagonizing the occupancy of the heterochromatin protein HP1γ [51].  JMJD2B has 
been shown to associate with the MLL-2 complex and Estrogen Receptor-α (ERα) and 























Figure 1.4: Domain architecture of the human JMJD2 enzymes. Domain boundaries were 
obtained from UniProt (http://www.uniprot.org): JMJD2A (O75164), JMJD2B (O94953), 




[60-62]. Although the biological functions of JMJD2D are still being explored, recent studies 
have shown that JMJD2D demethylates H3K9me3 in upstream enhancer elements of the 
macrophage-derived chemokine (Mdc) and Interleukin 12B (Il12b) loci and regulates the 
expression of these genes in a cell type specific manner [63]. Functional studies on the JMJD2 
enzymes have also been performed in lower eukaryotes. Knockdown of the single JMJD2 
homolog in C.elegans increased H3K9me3 and H3K36me3 levels in the pachytene regions and 
resulted in germ line apoptosis and altered progression of double strand break repair [45]. In 
addition, depletion of JMJD2A in chick embryos resulted in neural crest specification defects 
primarily due to impaired demethylation of the repressive mark H3K9me3 from neural crest 
specifier genes such as Sox10 and Snail2 [57]. 
 The involvement of JMJD2 enzymes in tumorogenesis and other diseases is generally 
better understood than their biological functions. Because of their important roles in AR 
signaling, not surprisingly, JMJD2A, JMJD2C and JMJD2D have been implicated in the onset 
and progression of prostate cancers [58, 59]. JMJD2B has been shown to promote breast, colon 
and gastric cancers [60-62, 64-66]. In addition, JMJD2B removes H3K9me3 at pericentric 
heterochromatin and increases chromosomal instability, a hallmark of most cancers [44]. 
JMJD2D has been described as a ‘pro-proliferative’ molecule and shown to promote colon 
cancer cell proliferation [67]. A comprehensive list of the functions and disease implications of 
JMJD2 enzymes is provided in Table 1.2.  
 
JMJD2 KDMs as Drug Targets 
Due to their roles in the onset and progression of different cancers, significant effort has 
































































challenges in developing inhibitors for these enzymes has been achieving selectivity for the 
JMJD2 homologs. Many inhibitors that are 2-OG analogs often target a large group of JmjC 
enzymes and many 2-OG dependent dioxygenases [68-70, 72]. Although these molecules may be 
viable probes to study enzyme functions in vitro and in vivo, their use in therapy is questionable 
due to their lack of selectivity for different JmjC families. Certain JmjC KDMs have differential 
functions in the context of cancer. For example, most of the JMJD2 KDMs are oncogenes 
whereas the UTX family of enzymes functions as tumor suppressors. Hence, efforts have been 
channeled toward designing inhibitors that are more selective to specific families of 
demethylases by exploiting their different substrate specificities. More recently, a bisubstrate 
analog fusing 2-OG and an H3K9 peptide has been developed and crystallized with JMJD2A, 
illustrating the potential of bisubstrate peptido-mimetics to inhibit specific families of JmjC 
KDMs [73]. The availability of more JmjC-peptide complex structures and understanding the 
mechanisms of substrate recognition will be highly beneficial in the design of additional, more 
selective inhibitors.  
 
Methylation Site and State Specificities in the JMJD2 KDMs 
The various biological functions of JMJD2 KDMs are largely dependent on their 
methylation site and state specificities. Despite the high sequence identity within the catalytic 
domains (>75%), there is a surprising degree of variability in the methylation site and state 
specificities among JMJD2 homologs. JMJD2A, JMJD2B and JMJD2C display dual specificity 
in demethylating H3K9me3 and H3K36me3. These methylation marks encode for distinct 
biological functions – transcriptional repression and transcriptional elongation respectively [27, 
45]. Hence it is conceivable that JMJD2A, JMJD2B and JMJD2C might be involved in a subset 
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of processes, each requiring either demethylation of H3K9me3 or H3K36me3 or both. In 
contrast, JMJD2D is specific for H3K9me3 and completely lacks activity toward H3K36me3 
[45]. An additional level of variation in specificity arises in the methylation state specificity 
within this family. JMJD2A, JMJD2B and JMJD2C are efficient at demethylating trimethylated 
H3K9 and H3K36 but have very weak activity toward dimethylated lysines. On the other hand, 
JMJD2D is efficient toward H3K9me3 and H3K9me2 [45]. Different methylation states can also 
encode for varied functions. A classic example is the methylation states associated with H3K9 
site. High-resolution Chromatin Immunoprecipitation (ChIP) experiments combined with DNA 
sequencing revealed that H3K9me3 and H3K9me2 are highly prevalent in heterochromatin 
regions whereas H3K9me1 is more abundant in active promoters near the Transcription Start 
Sites (TSS) [9]. Differential methylation states can also affect the binding of effector proteins 
such as HP1 which preferentially recognize H3K9me3 and H3K9me2 and have weak affinity for 
H3K9me1 [13, 14]. Thus the methylation site and state specificities of the JMJD2 enzymes could 
largely dictate the biological functions of different members of this family.  
 
Objectives of This Work 
The molecular mechanisms by which JMJD2 homologs achieve selectivity for specific 
methylation sites and states remains poorly understood. Although structures of JMJD2A have 
been solved by several groups [74-76], a detailed mechanism describing the site and state 
specificity of the JMJD2 family has remained elusive, primarily due to lack of structural and 
biochemical elucidations for other JMJD2 homologs, particularly JMJD2D. In this work, we 
determined the first crystal structure of human JMJD2D in the apoenzyme form and in complex 
with 2-OG and an H3K9me3 peptide (Chapter 3). We then performed structural comparisons 
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with JMJD2A, molecular docking analyses with H3K36me3 and biochemical studies with an 
array of histone peptide substrates to study how JMJD2 enzymes recognized H3K9me3 and why 
JMJD2D lacked specificity for the H3K36me3 site (Chapter 4). We also explored the active site 
of JMJD2A and JMJD2D and deciphered the methylation state specificity determinants in these 
enzymes (Appendix A). We used unnatural amino acids as a tool to manipulate an active site 
tyrosine and investigate the role of the CH•••O hydrogen bonds formed by this residue in 
JMJD2A demethylation (Appendix A). A crucial step to performing all the biochemical analyses 
described in Chapter 4 and Appendix A was the development of a viable biochemical assay that 
provided reproducible results and allowed for the accurate measurement of kinetic parameters. 
The development of a Strep-Tactin affinity based purification of recombinant JmjC KDMs along 
with the optimization of the formaldehyde dehydrogenase (FDH) - coupled demethylase assay is 
described in Chapter 2. These set of optimization experiments were critical to performing kinetic 
analyses describing the methylation site (Chapter 4) and state specificities (Appendix A) of 
JMJD2A and JMJD2D. Together, our studies furnish a fundamental understanding of the 
molecular mechanisms of site and state specific demethylation within the JMJD2 family of 
KDMs and these findings will be instrumental in deciphering the biological functions of these 
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CHAPTER 2 
OPTIMIZATION OF THE FORMALDEHYDE DEHYDROGENASE-COUPLED 
LYSINE DEMETHYLASE ASSAY FOR JUMONJI ENZYMES 
 
The JmjC demethylases have often been considered inherently weak enzymes and many 
experts have postulated the need for accessory factors to enhance enzymatic activity [1, 2]. 
Previously reported turnover numbers for these enzymes were ~ 0.01 min-1 which is over two 
orders of magnitude lower than the LSD family of lysine demethylases [3-9]. There are a number 
of biochemical methods available to assay the JmjC demethylases both qualitatively and 
quantitatively. Most studies on JmjC enzymes employ immunoblot analysis and mass 
spectrometry-based assays that can qualitatively assess changes in lysine methylation states [10, 
11]. Quantitative methods to measure demethylase activity have also been reported, including an 
amplified luminescent proximity homogeneous assay that detects changes in lysine methylation 
state via antibodies [12] and assays that rely on formaldehyde detection such as the Nash 
reaction [13], nuclear magnetic resonance (NMR) spectroscopy [14], and a formaldehyde 
dehydrogenase-coupled assay [7].  
 
The Formaldehyde Dehydrogenase (FDH) Coupled Demethylase Assay 
One of the most widely used assays to kinetically analyze JmjC enzymes is the FDH-
coupled demethylase assay. The scheme of this assay is depicted in Figure 2.1. The 











Figure 2.1: Schematic of the FDH-coupled Demethylase Assay. The JmjC KDM hydroxylates 
the methyllysine substrate using the co-substrates 2-OG, Fe(II) and O2 to yield the demethylated 
lysine, formaldehyde, CO2, and succinate. The formaldehyde released during the reaction is 
oxidized by FDH, which concomitantly reduces NAD+ to NADH. The NADH fluorescence is 
measured using an excitation wavelength of 340 nm and emission wavelength of 490 nm.   
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formaldehyde and succinate as by-products (Figure 1.2 in Chapter 1). The production of 
formaldehyde is continuously monitored via FDH, the coupling enzyme. FDH oxidizes 
formaldehyde to formic acid and the cofactor nicotinamide adenine dinucleotide (NAD+) is 
concomitantly reduced to NADH. The fluorescence of NADH (λex = 340 nm; λem = 490 nm) is 
measured and is used to calculate the rate of demethylation. Previously reported kinetic 
parameters for JmjC enzymes were determined using the FDH-coupled demethylase assay [7]. In 
these studies, hexahistidine-tagged JmjC enzyme was recombinantly purified by immobilized 
metal affinity chromatography (IMAC) and was subsequently used in the FDH-coupled assay.  A 
major caveat with purifying the enzymes in this manner is contamination by transition state 
metals such as Ni(II) and Co(II).  
 
Inhibition of JmjC KDMs by Transition State Metals 
 A number of groups have shown that transition state metals can inhibit JmjC 
demethylases. Chen et al have shown that the JmjC KDM, JMJD1A is inhibited by Ni(II) [15, 
16]. They determined an IC50 of 25 µM for Ni(II) and showed that Ni(II) occupies the active site 
of JMJD1A. In addition, they reported that the addition of catalytic Fe(II) up to 2 mM was 
unable to displace the Ni(II) from the active site suggesting that the inhibition by Ni(II) was 
irreversible. In addition they also provided evidence that Ni(II) inhibits JMJD1A in cells and 
suggested that Ni(II) inhibition of 2-OG-dependent dioxygenases could lead to metal toxicity and 
promote carcinogenesis [15]. Sekirnik et al reported that JMJD2A was inhibited by a range of 
transition state metals such Ni(II) [IC50= 10.3 µM],Co(II) [IC50=5.3 µM] , and Cu(II) [IC50=0.5 
µM] and the inhibition by these metals was prevalent even with 50-100 µM Fe(II) [17]. 
Previously reported kinetic analysis of JmjC KDMs was performed using hexa-histidine tagged 
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enzymes purified on Ni(II) IMAC columns and the turnover numbers for these enzymes were 
much lower than the FAD-dependent demethylase LSD1 [3-7]. We hypothesized that 
purification of JmjC KDMs on Ni(II) columns could lead to Ni(II) contaminated enzymes. Since 
the inhibition by Ni(II) is irreversible and addition of up to 100-fold excess Fe(II) does not 
displace Ni(II) from the active site, we proposed that the use of Ni(II)-inhibited enzymes in 
demethylase assays may be incompatible to determining accurate kinetic parameters.  To 
minimize transition state metal contamination, we adopted a Strep-Tactin purification scheme for 
the JmjC KDMs, JMJD2A and JMJD2D. In addition, we also optimized the various reagents, 
including the histone substrates, used in FDH-coupled demethylase assay and determined the 
kinetic parameters of Strep-Tactin column purified JMJD2 KDMs. Together, these results 
demonstrate that the purification of JMJD2 KDMs using a metal-free Strep-Tactin column yields 
highly active enzymes and provides a reliable tool for their biochemical characterization.    
 
MATERIALS AND METHODS 
Expression and Purification of Strep(II)-Tagged JMJD2A and JMJD2D 
The Strep-Tactin method of purification using Strep(II) affinity tags was originally 
reported by Schmidt and Skerra as a one-step protein purification and detection/capture method 
[18]. The catalytic domains of human JMJD2A (residues 1–350) and human JMJD2D (residues 
12–342) were cloned into the pST4 vector, a variant of pET15b (Novagen) that encodes the 
enzymes with an N-terminal Strep(II) tag (WSHPQFEK) followed by a tobacco etch virus (TEV) 
protease cleavage site to facilitate tag removal. KDMs were expressed in Escherichia coli 
Rosetta 2 (DE3) cells (Novagen). Cells were initially grown at 37º C and when the cell density 
(optical density) was 0.4-0.6, protein expression was induced using 1 mM (final concentration) 
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isopropyl thiogalactoside (IPTG) overnight at 18º C (for JMJD2A) or 16º C (for JMJD2D). The 
pelleted cells were re-suspended in Buffer A (100 mM Tris (pH 7.5) and 500 mM NaCl) and 
stored at -20º C. The KDMs were purified on a refrigerated FPLC system using a 5.0 ml Strep-
Tactin affinity column (Qiagen). Prior to a new purification, the column was freshly regenerated 
with four column volumes of 1X regeneration buffer followed by equilibration with four column 
volumes of Buffer A for optimal yield.  A 150 ml superloop was used to inject the sample onto 
the column. After sample injection, the column was washed with at least four column volumes of 
Buffer A to remove unbound sample. The KDMs were eluted with Buffer A containing 2.5 mM 
desthiobiotin (Sigma). Peak fractions (Figure 2.2) were pooled and incubated with 1 mg/ml TEV 
protease at 4º C overnight to remove the Strep(II) tag. The KDMs were then concentrated and 
purified by gel filtration chromatography using a Superdex 200 column (GE Healthcare) 
equilibrated in 20 mM Tris (pH 7.5) and 150 mM NaCl. The purity of the enzymes was assessed 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) (Figure 2.3). The 
KDMs were concentrated to 10–20 mg/ml, flash frozen in liquid nitrogen, and stored at -80º C. 
Protein concentration was determined by their absorbance at 280 nm in 6.0 M guanidinium 
chloride and 100 mM HEPES (pH 7.5) [extinction coefficients were calculated using ExPASy 
ProtParam (http://web.expasy.org/protparam): JMJD2A, ε280nm = 73,800 M-1 cm-1, and 
JMJD2D, ε280nm =70,820 M-1 cm-1]. 
 
Expression and Purification of Recombinant Formaldehyde Dehydrogenase 
 The Zn(II)-dependent glutathione-independent FDH from Pseudomonas putida was 
expressed in E.coli Rosetta 2 cells as a His-tagged fusion protein as previously reported [19]. 















Figure 2.2: Strep-Tactin purification of Strep(II)-tagged JMJD2A. Peak fractions of the 
Strep(II)-tagged enzyme were eluted from the Strep-Tactin column using desthiobiotin and were 
analyzed on a 12% SDS-PAGE gel stained with Coomassie Blue. Lane 1: Molecular weight 












Figure 2.3: Gel Filtration Purification of JMJD2A. Chromatogram of the Superdex 200 gel 
filtration purification of JMJD2A (solid line) overlaid with the molecular weight standards 
(dashed line). The JMJD2A catalytic domain elutes at the expected elution volume, 
corresponding to its molecular mass of 41 kDa. The inset panel depicts the coomasie blue stained 














grow overnight at 25º C. Cells were harvested in 50 mM HEPES (pH 8.0) and 500 mM NaCl and 
stored at -20º C. His-FDH was purified using an IMAC Sepharose column (GE Healthcare) 
charged with Zn(II) followed by Superdex 200 gel filtration chromatography, where the protein 
eluted as a monomer. The purity of the FDH was assessed by SDS–PAGE (Figures 2.4 and 2.5). 
Peak fractions were pooled and concentrated to 13 mg/ml, flash frozen in liquid nitrogen, and 
stored at -80ºC. Protein concentration was determined by absorbance at 280 nm in 6.0 mM 
guanidinium chloride and 100 mM HEPES (pH 7.5) [extinction coefficients were calculated 
using ExPASy ProtParam (http://web.expasy.org/protparam): FDH, ε280nm = 73,800 M-1 cm-1]. 
 
Substrate Histone Peptides 
 A 15-residue histone H3 peptide with a trimethylated Lys9 and C-terminal amidation 
(H3K9me3, sequence: ARTKQTAR-Kme3-STGGKA-amide) was synthesized by the Protein 
Structure Core Facility at the University of Michigan. To assess the efficacy of substrates 
bearing Methyllysine Analogs (MLAs), an analogous H3K9C peptide was also synthesized. The 
H3K9C peptide was alkylated with (2-bromoethyl)trimethylammonium bromide (Aldrich) to 
install a trimethyllysine analog at Cys9 (H3K9Cme3) according to the protocol of Simon and 
coworkers [20]. The H3K9me3 and H3K9Cme3 peptides were purified by reverse phase high-
performance liquid chromatography (HPLC) with chloride as the counter ion, and net peptide 
content was determined by amino acid analysis. 
 
Determination of Metal Content of JMJD2A and JMJD2D  
 Analysis of transition metals in JMJD2A and JMJD2D was performed using a Thermo 
Scientific Element inductively coupled plasma high-resolution mass spectrometer (ICP–HRMS) 
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in the W. M. Keck Elemental Geochemistry Laboratory in the University of Michigan’s 
Department of Geological Sciences. 200 µl of a 20 µM protein sample was submitted for metal 
detection and multiple purifications of StrepTactin column purified JMJD2A and JMJD2D were 
analyzed. As a control, the metal content of different batches of Ni(II) column purified JMJD2D 
was also determined. The transition metal concentrations in the gel filtration buffer were 
measured and subtracted from the metal concentrations in the protein samples. The percent metal 
content was determined by: 
 
% metal content = metal concentration in sample(μM)-metal concentration in buffer (μM)
protein concentration (μM)
× 𝟏𝟎𝟎 % 
 
Reagents for the FDH-Coupled Demethylase Assay 
 In addition to the Strep(II)-tagged KDMs, recombinant FDH and histone peptides, the 
following reagents were used in the assay: L-Ascorbic acid, NaCl, and HEPES were purchased 
from Fisher Scientific. Ammonium iron(II) sulfate [(NH4)2Fe(SO4)2] and 2-OG (acid) were 
obtained from Fluka. NAD+ and NADH were purchased from Roche. All buffers were prepared 
using water purified by a Milli-Q Biocel System (Millipore), yielding a resistivity of 18.2 MΩ. 
L-Ascorbic acid and (NH4)2Fe(SO4)2 were stored in a desiccator under vacuum to minimize 
oxidation of the reagents. The concentration of all the reagents used in the FDH-coupled 
demethylase assay was optimized. Sample optimization plots for 2-OG and FDH are shown in 
Figures 2.6 and 2.7 respectively.  
 
Setting up the FDH-Coupled Demethylase Assay 
















Figure 2.4: Purification of recombinant FDH on S200 column.  Lane 1: Molecular Weight 
Standards; Lane 2: Pooled fractions from Zn column; Lane 3: empty; Lane 4: Fractions from Zn 
column concentrated to 2 ml; Lane 5: empty; Lane 6: FDH sample from previous purification; 
Lane 7-Lane 14: Fractions 15-22 from S200 column after sample in Lane 4 was injected into the 
column. The bands at ~120 kDa are most likely FDH samples that were not properly reduced 

















Figure 2.5: FDH samples with excess Dithiothreitol (DTT). FDH samples after gel filtration 
purification were prepared with excess DTT and heated for 5 min at 90ºC for complete reduction 
of disulfide linkages. Lane 1: Molecular Weight Standards; Lane 2 and Lane 3: Concentrated 
FDH samples after S200 purification were reduced using DTT and loaded on the gel.  The last 
two lanes represent the samples on Lanes 2 and 3 loaded without reducing agents. This resulted 














Figure 2.6: Optimization of 2-OG concentration in the coupled demethylase assay. 
Increasing 2-OG concentrations (0 µM, 200 µM, 500 µM, and 1 mM) were included in the assay 
cocktail with 1.0 µM JMJD2A and 700 µM H3K9me3 peptide substrate. The optimal assay 


















Figure 2.7: Optimization of the FDH concentration in the coupled demethylase assay. 
Increasing FDH concentrations (0 nM, 50 nM, 100 nM, 200 nM and 300 nM) were included in 
the assay cocktail with 1.0 µM JMJD2A and 700 µM H3K9me3 peptide substrate. The optimal 





HEPES (pH 7.5), 50 mM NaCl, 50 µM (NH4)2Fe(SO4)2, 1 mM L-ascorbic acid, 1 mM NAD+, 
0.1 µM FDH, 1 mM 2-OG and variable concentrations of JMJD2 enzyme and H3K9me3 peptide 
substrate. The concentrations mentioned above were for a total assay volume of 100 µL. For 
determining the linear range of enzyme concentration, 700 µM H3K9me3 peptide was used and 
the concentration of the KDM was varied from 0.0-2.0 µM for JMJD2A and 0.0-1.0µM for 
JMJD2D. For performing the Michaelis–Menten kinetics, the KDM concentration was kept 
constant (1 µM JMJD2A and 0.5 µM JMJD2D) and the H3K9me3 peptide concentration was 
varied from 0-700 µM. To maintain optimal and reproducible activity in the assay, the 
(NH4)2Fe(SO4)2 and L-ascorbic acid stock solutions were prepared fresh every 2 hours to reduce 
their oxidation. For a 100 µL assay, 75 µL of the assay cocktail containing HEPES (pH 7.5), 
NaCl, (NH4)2Fe(SO4)2, L-ascorbic acid, NAD+, FDH and KDM was prepared separately from 25 
µl of the substrate cocktail containing H3K9me3 peptide and 2-OG. The assay and substrate 
cocktails were pipetted into 96-well black polypropylene plates (Corning Scientific) and 
incubated at 37º C in the plate reader for 3-4 min. Reactions were initiated by the addition of the 
substrate cocktail into the assay cocktail to produce a final volume of 100 µl. Care was taken to 
avoid any air bubbles in the wells and the plate was gently tapped before insertion into the plate 
reader. NADH fluorescence was measured every 30 sec for a period of 5–10 min using a Tecan 
Safire2 microplate reader with excitation and emission wavelengths of 340 and 490 nm, 
respectively. Table 2.1 provides a detailed template outlining the assay setup.  
 
NADH Calibration Assay 
 To determine the gain setting for the plate reader and to calculate the rate of 





Table 2.1: Step-wise protocol for performing the FDH-coupled demethylase assay 
 
All reagent concentrations represent the final concentration in the 100 μL assay volume. 
Depending on the type of microplate reader, the gain and Z-position are optimized using the 
NADH calibration assay (next section). For all the assays used in this study, a gain setting of 86 






75μL of assay cocktail is added 
to a well in a black 96 well plate 
 
 
HEPES 7.5 (50 mM)  
NaCl (50 mM)  
(NH4)2Fe(SO4)2 (50 μM)* 
L-Ascorbic Acid (1 mM)* 
NAD+ (1 mM) 
FDH (100 nM) 
KDM (variable) 
Water (to adjust volume to 75 μL) 
 
* Prepared fresh  
 
25μL of substrate cocktail is  
added to a separate well 
 
H3K9me3 peptide (variable)  
2-OG (1 mM) 
Water (to adjust volume to 25 μL) 
 
Incubate the cocktails in the microplate at 37 ºC for at least 3-4 min. 
Initiate the assay by pipetting substrate cocktail into assay cocktail and avoiding bubbles. 
Continuously monitor NADH fluorescence for 5-10 min in 30 sec intervals. 




The stock concentration of NADH was accurately determined by measuring the absorbance at 
340 nm in a spectrophotometer (NADH ε340nm = 6220 M-1 cm-1). To perform the calibration 
assay, the assay cocktail from Table 2.1 was used in the absence of the KDM. A range of NADH 
concentrations (0.0-10.0 µM) was used in place of the substrate cocktail. After adding NADH to 
the assay cocktail, fluorescence was measured using the ‘endpoint’ setting in the plate reader. If 
the gain setting of the instrument was to be measured, the NADH calibration assay was 
performed under the ‘optimal’ gain setting and the gain setting determined by the instrument was 
used in all subsequent assays by inputting this gain under the ‘manual’ gain setting. The detailed 
set up of the NADH calibration curve and a sample plot are shown in Table 2.2 and Figure 2.8 
respectively.  
 
Determination of Kinetic Parameters 
 The FDH-coupled demethylase assay was performed in 30 sec intervals for at least 5 min. 
Relative fluorescence units (RFU) versus time was plotted and the slope (RFU/min) was 





v0   =   rate of NADH formation (µM NADH min-1)   =  slope of KDM assay (RFU/min) 
       -------------------------------------------- 
       slope of NADH calibration curve  
        (RFU/µM NADH)  
 
Initial velocities (v0) were then plotted as a function of substrate concentration, and the following 
Michaelis–Menten equation was fit to the data using Prism (GraphPad Software) to calculate the 







Table 2.2: Step-wise protocol for performing the NADH calibration assay 
 
.  
All reagent concentrations represent the final concentration in the 100 μL assay volume   
Step Reagent 
 
75μL of assay cocktail is added 
to a well in a black 96 well plate 
 
 
HEPES 7.5 (50 mM)  
NaCl (50 mM)  
(NH4)2Fe(SO4)2 (50 μM)* 
L-Ascorbic Acid (1 mM)* 
NAD+ (1 mM) 
FDH (100 nM) 
2-OG (1 mM) 
Water (to adjust volume to 85 μL) 
 
* Prepared fresh  
 
25μL of NADH cocktail is  
added to a separate well 
 
NADH (use a range from 0-10 µM) Example: (0 µM, 3.3 
µM, 6.6 µM, 10 µM) 
Water (to adjust volume to 15μL) 
 
Incubate the cocktails in the microplate at 37 ºC for at least 3-4 min. 
Pipet NADH cocktail into assay cocktail and avoiding bubbles. 
Monitor NADH fluorescence using Endpoint mode in the plate reader. Determine gain setting 
of the instrument.  
Plot relative fluorescence units (RFUs) versus NADH concentration and calculate the slope 














Figure 2.8: NADH calibration curve. RFUs were plotted as function of NADH concentration. 
The calibration curve data were measured just before or concomitantly with the KDM assays. 
The calibration curve shown here represents the fluorescence values measured at time = 0 min. 




v0 = kcat [ETotal][S] / (Km + [S]) 
 
where  
v0  = initial velocity, µM NADH min-1 
kcat  = turnover number, min-1 
ETotal = total enzyme concentration, µM 
[S]  = substrate concentration, µM 
Km = substrate concentration yielding half-maximal velocity, µM 
 
For peptides with high background drift, a control assay was run in the absence of KDM and the 
slope of RFUs versus time was determined. This was subtracted from the slope of RFUs versus 
time for all subsequent assays performed in the presence of KDM. 
 
RESULTS 
Purity of Recombinant Formaldehyde Dehydrogenase 
 Previous kinetic analyses using the FDH-coupled demethylase assay were carried out 
using commercially available FDH (Sigma). However, we had observed that these samples 
usually contain a large amount of bovine serum albumin (BSA) most likely added to stabilize the 
FDH. Many groups have shown that BSA has a propensity to chelate divalent metal ions and can 
catalyze the oxidation of Fe(II) to Fe(III) [21-24]. We hypothesized that using commercial FDH 
contaminated with BSA might be incompatible with the demethylase assay because the BSA 
could potentially deplete Fe(II) in the assay cocktail, and decrease the amount of Fe(II) available 
for the KDM. To circumvent this issue, we purified recombinant FDH from P.putida using 
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Zn(II) affinity column and gel filtration chromatography (Figures 2.4 and 2.5). We used a Zn(II) 
affinity column because FDH is a Zn(II) dependent metalloenzyme. Recombinant FDH purified 
by this method was not only of high purity, but was highly active and very compatible with the 
demethylase assay (Figure 2.7).  
 
Purity of Strep(II)-Tagged JMJD2A and JMJD2D 
We purified Strep(II)-tagged JMJD2A and JMJD2D using a two-step protocol : an 
affinity chromatography step on a Strep-Tactin column followed by gel filtration after tag 
removal. We noticed that the purity of the samples (as seen on an SDS PAGE gel) was high 
following the first affinity purification step (Figure 2.2). Hence, the Strep-Tactin column could 
be used as a one –step purification protocol to obtain highly pure recombinant protein. We 
purified the protein samples by gel filtration chromatography after overnight Strep(II)-tag 
cleavage by TEV protease and this yielded highly pure protein (Figure 2.3). 
 
Metal Content Analysis of Strep(II)-Tagged JMJD2A and JMJD2D 
 We adopted a Strep-Tactin purification system to reduce the amounts of inhibitory 
transition state metals and obtain reliable kinetic parameters. To verify whether switching the 
conventional hexahistidine-Ni(II) sepharose purification to a Strep(II)-Strep-Tactin purification 
reduced the transition state metal content, we analyzed multiple Strep-Tactin purifications of 
JMJD2A and JMJD2D by ICP-HRMS (Table 2.3). As a control, we also analyzed the metal 
content of a three samples of Ni(II) column purified JMJD2D. The data clearly revealed that the 
Strep-Tactin purified enzymes have substantially lower amounts of transition state metals such as 








Table 2.3: Transition state metal content analysis of JMJD2A and JMJD2D 
 
 
 * Ni content range for three different batches of Ni(II) column purified JMJD2D.   
















     
Zn 98 93 84 90.3 92 
Fe 16 14 5.8 5.9 8.1 
Ni 5.6 5.4 2.4 1.8 40-100* 
Mg 0.50 0.50 N.D. 1.4 N.D. 
Ca 0.50 0.50 N.D. N.D. N.D. 
Co 0.17 0.09 0.15 0.19 N.D. 
Mn 5.7 2.5 0.51 0.41 0.47 
Cu 0.010 0.13 0.79 0.50 0.17 
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consistent with the fact that JMJD2 KDMs contain a structural Zn-finger (Chapter 3). The 
percentage of other transition state metals except Fe was lower than 6%. We observed up to 16% 
Fe content in the JMJD2A samples suggesting that minor quantities of residual Fe co-purified 
with the enzyme. We also analyzed the metal content of three samples of Ni(II)-column purified 
JMJD2D. We observed close to 100% Zn corresponding to the structural Zn-finger and the 
percentage of Co, Cu, Ca and Mn were less than 6%. Strikingly however, the amount of Ni in 
these samples ranged from 40-100% suggesting that a significant amount of the metal had 
leached from the column. We concluded that Ni(II) was potentially bound in the active site with 
very high affinity because 40-100% Ni was prevalent even after extensive dialysis and gel 
filtration. The metal analysis data clearly showed that purifying KDMs on a Ni(II) column led to 
increased inhibitory metal contamination and adopting the Strep-Tactin column purification 
helped us overcome this issue.  
 
Kinetic Analysis 
We performed extensive kinetic analysis on JMJD2A and JMJD2D that were purified 
using the Strep-Tactin affinity system using the optimized FDH-coupled demethylase assay. In 
all the assays, the substrate used was an H3K9me3 peptide spanning residues 1-15 of histone H3, 
trimethylated at Lys 9. We first tested the linearity of enzyme concentration with initial velocity 
using 0.0-2.0 µM JMJD2A and 0.0-1.0 µM JMJD2D. We observed a linear relationship between 
enzyme concentration and initial velocity for both enzymes (Figure 2.9). Based on this test, we 
used 1.0 µM JMJD2A and 0.5 µM JMJD2D and measured the kinetic parameters for 
demethylation of an H3K9me3 peptide substrate. We performed this analysis with replicate 














Figure 2.9: Linearity between JMJD2 enzyme concentration and initial velocity. Initial 
velocities were plotted as a function of JMJD2A (▲, 0.0–2.0 µM) and JMJD2D (●, 0.0–1.0 µM) 
concentration under conditions with a fixed substrate concentration (700 µM H3K9me3 peptide). 
The error bars represent standard deviations calculated from triplicate measurements for each 
data point. A linear regression was calculated for the data points corresponding to each enzyme. 
For the concentration ranges tested, both enzymes exhibited a linear relationship between 




H3K9me3 peptide for both the enzymes (Figure 2.10 and 2.11). These values were within 2-fold 
of the Km values previously reported for hexahistidine-tagged JMJD2A and JMJD2D assayed 
with the same-length H3K9me3 peptide substrate [7]. In contrast, the average kcat values of 
Strep(II)-tagged JMJD2A were 1.8 min-1 and that of Strep(II)-tagged JMJD2D was 4.0 min-1 
which were approximately 100- and 50-fold higher, respectively, than those previously measured 
for hexahistidine-tagged enzymes [7]. Our kinetic data clearly illustrate that the reduction in 
inhibitory transition state metals combined with the optimized assay resulted in enhanced 
enzymatic activity for the JMJD2 KDMs.  
 
Use of Methyllysine Analog Bearing Substrates 
Simon et al designed a method to site specifically install methyl-lysine analogs (MLAs) 
in full length histones and histone peptides [20] for use in biochemical analysis. This technique 
involves mutating the lysine of interest to a cysteine followed by alkylation via a halogenated 
ethylamine that is mono-, di-, or trimethylated (Figure 2.12). Using this protocol, we alkylated an 
H3K9C peptide to form an H3K9Cme3 peptide. After alkylation, the product was HPLC purified 
and homogeneity of the product was analyzed by Electrospray Ionization-Mass Spectrometry 
(ESI-MS). When we assayed the activity of JMJD2A for the H3K9Cme3 peptide, we observed 4-
fold increase in the Km and 9-fold decrease in kcat/Km compared to the H3K9me3 peptide of same 
length bearing a bona fide trimethyllysine (Figure 2.13 and Table 2.4).  These findings illustrate 
that histone peptides bearing MLAs are suboptimal substrates for the JMJD2 enzymes compared 
to their bona fide methyllysine counterparts. Hence, biochemical studies and kinetic parameters 











Table 2.4: Kinetic constants of replicate purifications of Strep-Tactin column purified 














Km (µM) 96 ± 13 96 ± 7.9 102 ± 9.5 120 ± 18 
kcat (min
-1
) 1.7 ± 0.081 1.9 ± 0.05 3.3 ± 0.05 4.7 ± 0.12 


















Figure 2.10: Kinetic analysis of JMJD2A and H3K9me3. Michaelis–Menten plot of initial 
velocity as a function of H3K9me3 peptide concentration for JMJD2A. 1.0 µM enzyme was used 
in this assay. The error bars represent standard deviation calculated from triplicate 















Figure 2.11: Kinetic analysis of JMJD2D and H3K9me3. Michaelis–Menten plot of initial 
velocity as a function of H3K9me3 peptide concentration for JMJD2D. 0.5 µM enzymes was 
used in this assay. The error bars represent standard deviation calculated from triplicate 






































Figure 2.13: Kinetic analysis of JMJD2A and H3K9Cme3. Michaelis Menten plot of JMJD2A 
assayed with the H3K9Cme3 peptide substrate. The kinetic parameters for the H3K9Cme3 





Since their discovery, relatively low enzymatic activities have been reported for the JmjC 
KDMs and this has opened questions concerning their biological activities and the possibility 
that they may need posttranslational modifications and other accessory factors or act on 
alternative substrates [1, 2]. Turnover numbers reported for these enzymes generally ranged from 
0.01 to 0.5 min-1 [7-9]. By comparison, the kcat  values for the FAD dependent demethylase, 
LSD1 ranged from 2 to 12 min-1 toward H3K4me2 peptide substrates, according to kinetic 
studies published by several groups [3-6]. Previous studies on the JmjC enzymes have employed 
hexahistidine-tagged KDMs, which may have contained sub-stoichiometric concentrations of 
transition metals introduced during IMAC purification. Indeed, many studies have illustrated the 
susceptibility of JmjC enzymes to inhibition by these metal ions. For example JMJD2E is 
inhibited by transition metals used in IMAC, such as Ni(II), Co(II), Zn(II), and Cu(II), with IC50 
values ranging between 0.5 and 15 µM, depending on the metal type [25]. These findings are 
consistent with in vitro and in vivo studies reporting inhibition of JMJD1A and JMJD2A by 
Ni(II) and Co(II), respectively [15, 25-28]. Transition metal ions can competitively inhibit JmjC 
KDMs through binding to the His-Glu/Asp-His triad that coordinates Fe(II) within the active site 
[7, 29, 30]. Furthermore, certain transition metal ions, such as Co(II) and Ni(II), can indirectly 
inhibit JmjC enzymes by catalyzing the oxidation of ascorbic acid, that maintains the redox 
balance in the demethylase assay. To overcome these issues, we employed a Strep-Tactin affinity 
purification system that yielded highly active recombinant JmjC KDMs. Notably, the Strep-
Tactin purification provided a convenient method for isolating JmjC KDM apoenzymes that 
could be reconstituted with Fe(II) or other divalent transitional metal ions for biochemical 
studies. In addition, this approach minimized contamination by divalent transition metal ions as 
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shown by the ICP-HRMS data (Table 2.3). The turnover numbers for Strep-Tactin purified 
JMJD2A and JMJD2D measured using our optimized FDH-coupled demethylase assay were 
~50-100 fold greater than those reported for their Ni(II) column purified counterparts [7]. Our 
findings emphasize that KDMs from the JmjC and LSD1 families display comparable lysine 
demethylase activity in vitro and suggest that these enzymes may possess similar activity profiles 
toward chromatin in living cells. These protocols can be extended to other families of JmjC 
demethylases such as the UTX and JMJD3 enzymes and other dioxygenases. In summary, these 
findings highlight the advantages of using affinity tags that are compatible with transition metal-
free purification, such as the Strep(II)-tags, when isolating recombinant JmjC KDMs for 
functional studies as described in Chapters 4 and Appendix A. 
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METHYLATION SITE SPECIFICITY STUDIES - CRYSTAL STRUCTURE OF 
HUMAN JMJD2D 
  
 The human JMJD2 family comprises four members- JMJD2A, JMJD2B, JMJD2C and 
JMJD2D. These enzymes are characterized by an N-terminal JmjN domain followed by the 
catalytic JmjC domain and a large C-terminal region. Most homologs possess addition Tudor and 
PHD domains (Figure 1.4 from Chapter 1). This family of enzymes has been implicated in a 
wide range of biological functions including neuronal development (JMJD2A), androgen 
receptor signaling and prostate development (JMJD2A, JMJD2C and JMJD2D), estrogen 
receptor signaling (JMJD2B) [1-10]. Despite the high degree of sequence identity (>75%) within 
their catalytic domains (Figure 3.1), the JMJD2 KDMs are quite distinct in their substrate 
specificities.  All members of the JMJD2 family can demethylate H3K9me3, a repressive mark 
and corroboratively these enzymes have been implicated in transcriptional activation [1, 5, 10-
25]. In addition, JMJD2A, JMJD2B and JMJD2C can also demethylate H3K36me3, a chromatin 
modification that is associated with the elongating form of RNA Polymerase II [7, 26-31]. 
JMJD2D, on the other hand, lacks specificity for the H3K36me3 site and is highly specific for 
H3K9me3/me2 [32]. The molecular mechanisms by which these enzymes achieve selectivity for 
specific sites have not been well studied. Although a number of crystal structures of JMJD2A in 
complex with both H3K9me3 and H3K36me3 were solved [33-35], these studies do not provide 






Figure 3.1: Sequence Alignment of the JMJD2 family of KDMs. The residues in different 
domains are colored: Purple: JmjN domain; Orange: Mixed domain; Red: JmjC domain and 
Green: C-terminal domain. Residues involved in metal coordination, 2-OG binding and Zn-
finger are highlighted in yellow, cyan and gray respectively [32, 34, 35]. 
  
JMJD2A          ----MASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPR 56 
JMJD2B          ---MGSEDHGAQNPSCKIMTFRPTMEEFKDFNKYVAYIESQGAHRAGLAKIIPPKEWKPR 57 
JMJD2C          --MEVAEVESPLNPSCKIMTFRPSMEEFREFNKYLAYMESKGAHRAGLAKVIPPKEWKPR 58 
JMJD2D          METMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKAR 60 
                     :.   . **...** * *: ***.:*.:*:**:**:*********::******.* 
 
JMJD2A          ASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEE 116 
JMJD2B          QTYDDIDDVVIPAPIQQVVTGQSGLFTQYNIQKKAMTVGEYRRLANSEKYCTPRHQDFDD 117 
JMJD2C          QCYDDIDNLLIPAPIQQMVTGQSGLFTQYNIQKKAMTVKEFRQLANSGKYCTPRYLDYED 118 
JMJD2D          ETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFED 120 
                  **:*.:::*.:*:**:.:*::*:****: :****** *:*::*** ** ** : :::: 
 
JMJD2A          LERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYL 176 
JMJD2B          LERKYWKNLTFVSPIYGADISGSLYDDDVAQWNIGSLRTILDMVERECGTIIEGVNTPYL 177 
JMJD2C          LERKYWKNLTFVAPIYGADINGSIYDEGVDEWNIARLNTVLDVVEEECGISIEGVNTPYL 178 
JMJD2D          LERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYL 180 
                ********  : .******:.*::::. . :**:. * *: *::*.*.*  ********* 
 
JMJD2A          YFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEA 236 
JMJD2B          YFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAIGFFPGSSQGCDA 237 
JMJD2C          YFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAQGFFPSSSQGCDA 238 
JMJD2D          YFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGA 240 
                *******:*****************:****:** :*****:******  :**.*::.* * 
 
JMJD2A          FLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRW 296 
JMJD2B          FLRHKMTLISPIILKKYGIPFSRITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATLRW 297 
JMJD2C          FLRHKMTLISPSVLKKYGIPFDKITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATVRW 298 
JMJD2D          FLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRW 300 
                *****::**** :**: ****.::********:******************: **** ** 
 
JMJD2A          IEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPT----PEAAE 352 
JMJD2B          IDYGKVATQCTCRKDMVKISMDVFVRILQPERYELWKQGKDLTVLDHTRPTALTSPELSS 357 
JMJD2C          IDYGKVAKLCTCRKDMVKISMDIFVRKFQPDRYQLWKQGKDIYTIDHTKPTPASTPEVKA 358 
JMJD2D          IDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDRAVVDHMEPRVPASQELST 360 
                *:*** *  *:* :  *.:*** *** :**:**.*** *:*  .:**  *      *    
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we determined the crystal structure of JMJD2D (this chapter) and performed structural 
comparisons, docking studies and biochemical analysis with an array of mutant and hybrid 
peptide substrates (Chapter 4). Our results yield new insights into the site-specific demethylation 
by JMJD2 enzymes and these studies will aid in understanding the biological functions of 
H3K9me3 and H3K36me3 demethylation.  
 
MATERIALS AND METHODS 
Cloning, Expression and Purification of His-JMJD2D 
 The catalytic domain of human JMJD2D (residues 12-342) was cloned into a variant of 
pET15b (Millipore EMD Biosciences) with a tobacco etch virus (TEV) protease cleavage site to 
facilitate removal of the N-terminal hexahistidine tag [34]. The enzyme was overexpressed in E. 
coli BL21 DE3 Rosetta 2 cells. Protein expression was induced by the addition of 1 mM IPTG 
and cells were allowed to grow at 16º C overnight. Cell pellets were re-suspended in Buffer A 
(100 mM Tris (pH 7.5) and 500 mM NaCl) and stored at -20ºC. Purification was performed 
using a refrigerated FPLC system and the enzyme sample was kept on ice at all other times to 
prevent protein precipitation. 150 µL of EDTA-free Halt protease inhibitor cocktail (Thermo) 
was added to each cell pellet (obtained from 1 liter of culture) before sonication to prevent 
proteolysis. Cell lysate was injected into a pre-equilibrated Ni(II) sepharose column (GE 
Healthcare) using a 150 ml superloop. After washing the column extensively (at least 4 column 
volumes), the protein was eluted using a linear gradient of Buffer B (Buffer A + 500 mM 
imidazole). Peak fractions (Figure 3.2) were pooled and 1 mg/ml TEV protease was added to 
facilitate removal of the hexahistidine tag. After tag removal, the sample was subject to batch 















Figure 3.2: Ni(II) column purification of JMJD2D. Lane 1: Molecular Weight Standards; 
Lane 2: Flow through from column; Lane 3-Lane10 : Fractions 5-13. The protein was purified 




and loaded on a Superdex 200 gel filtration column (GE Healthcare) pre-equilibrated with 20 
mM Tris (pH 7.5) and 150 mM NaCl. Peak fractions (Figure 3.3) were concentrated to 10-20 
mg/ml as determined by absorbance at 280 nm, flash frozen, and stored at –80° C.  
 
Crystallization of JMJD2D•2-OG•H3K9me3 Ternary Complex 
All crystallization experiments and crystal harvesting were performed at 4º C. Initial 
crystallization trials were set up using the commercially available sparse-matrix screening kits 
which included Index (Hampton), JCSG+ (Qiagen), Wizard (Emerald Biosystems), Structure 
Screen (Molecular Dimensions), PEGs I and II screens (Qiagen), Ammonium Sulfate screen 
(Qiagen), Cation Screen (Qiagen) and Anion Screen (Qiagen). Crystal drops were set up using 1 
µl of protein sample and 1 µl of mother liquor. Two protein samples were used in the 
crystallization screens- one sample was prepared with 10-12 mg/ml JMJD2D, 1.5 mM 2-OG and 
1.5 mM H3K9me3 peptide (New England Peptide) and the second sample was prepared without 
the peptide. To ensure the presence of the peptide in crystals, only conditions that yielded 
crystals in the presence of the peptide and not in its absence were pursued. Plate clusters were 
obtained in 0.3M Potassium Nitrate (KNO3) and 16% PEG 3350. To further optimize this 
condition and obtain diffraction quality crystals, we performed an additive screen (Hampton) and 
the manufacturers’ protocol was followed. The additive sodium thiocyanate produced the highest 
quality crystals which contained a combination of ‘flame’ and ‘diamond’ shaped crystals (Figure 
3.4). These conditions were further optimized in a 24-well hanging drop set up and we obtained 
reproducible crystals in 7% PEG 3350, 0.1 M sodium thiocyanate and 0.35M KNO3. Crystals 
were harvested by serial transfer into the crystallization solution supplemented with 5%, 15% 

















Figure 3.3: S200 purification of JMJD2D. Lane 1: Molecular Weight Standards; Lane 2: 
Before TEV cleavage; Lane 3: After TEV Cleavage, before batch binding; Lane 4: After batch 
binding; Lane 5: After concentration; Lane 7: Fraction 24 Lane 8: Fraction 26 Lane 9: Fraction 

















Figure 3.4: Crystals of the JMJD2D•2-OG•H3K9me3 ternary complex. ‘Flame’ and 








Optimization of Crystals by Surface Entropy Reduction 
Few crystallographic conditions were obtained in the sparse matrix screens with JMJD2D 
in the absence of the peptide. To enhance the crystallizability of the enzyme, the Surface Entropy 
Reduction (SER) method was used [36-39]. In the SER technique, high entropy amino acid 
residues (such as Lysines and Glutamates) that are surface exposed are mutated to smaller amino 
acids such as alanines which have low entropy side chains. High entropy amino acids on the 
surface are disfavored at protein-protein interfaces and could potentially diminish the chances of 
forming stable crystals. When we submitted the sequence of JMJD2D to the SER server [39], the 
top hit was four lysines in the enzyme- K91, K92, K93 and K94.  These lysines were clustered 
into two groups of mutations- (i) K91A/K92A and (ii) K93A/K94A. The enzymatic activity of 
these mutations was also verified prior to crystallization to ensure these mutations did not perturb 
catalysis. Crystal screens were set up using the commercially available spare-matrix screens 
listed above using 10 mg/ml protein and 1.5 mM 2-OG. Both mutation sets had a marked 
improvement in crystallizability of JMJD2D compared to the WT counterpart. Among the two 
mutation sets, the K93A/K94A mutant produced best quality crystals and only this mutant was 
pursued. ‘Diamond’ shaped crystals were obtained in 0.2 M calcium acetate, 0.1 M HEPES 7.5 
and 10% PEG 8000 (Figure 3.5). The crystals were optimized by vapor diffusion and were 
harvested by serial transfer into the crystallization solution supplemented with 5%,15%, and 25% 
glycerol and then flash frozen in liquid nitrogen. 
 
X-Ray Diffraction Data Collection, Processing and Structure Determination 
 Diffraction data were collected at the Life Sciences-Collaborative Access Team (LS-

















Figure 3.5: Crystals of JMJD2D apoenzyme (K93A/K94A). ‘Diamond’ shaped crystals were 
grown at 0.2 M calcium acetate, 0.1 M HEPES 7.5 and 10% PEG 8000.   
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the JMJD2D ternary complex diffracted to 1.8 Å and those from the K93A/K94A mutant (hereon 
referred to as apoenzyme) diffracted to 2.5 Å. The crystallographic statistics for both structures 
are listed in Table 3.1. Data was processed and scaled using HKL2000 [40]. Molecular 
replacement was performed using MOLREP [41] with a JMJD2A structure (PDB entry: 2Q8C) 
used as the search model for the JMJD2D ternary complex. The structure of the complex was 
subsequently used as a search model for the JMJD2D apoenzyme. Model building and 
refinement were conducted using Coot and Refmac, respectively [42, 43]. TLS refinement was 
used to improve the electron density maps of the JMJD2D apoenzyme [44, 45]. Simulated 
annealing omit maps were calculated using CNS [46, 47]. After refinement, structures were 
validated using MOLPROBITY [48]. Structural figures were rendered using PyMOL 
(Schrodinger, LLC).  
 
Note: For the remainder of Chapter 3, and the whole of Chapters 4 and 5, amino acid residues 
from the histone peptide substrates are denoted using the one letter code and enzyme residues are 
denoted using the three letter code.  
 
RESULTS 
Structure of JMJD2D Apoenzyme  
The crystal structure of the JMJD2D apoenzyme is shown in Figure 3.6. Although 2-OG 
was added to the protein solution during crystallization, we did not observe any appreciable 
electron density for the cofactor. However, strong density for the active site metal was seen. We 
modeled this metal as Ni(II), because the JMJD2D protein sample was purified on a Ni column 




 Table 3.1: Crystallographic Data and Refinement Statistics of JMJD2D 
  JMJD2D2-OGH3K9me3 JMJD2D apoenzyme 
RCSB PDB ID  4HON 4HOO 
Data Collection    
   Beamline  APS 21-ID-G APS 21-ID-G 
   Wavelength (Å)  0.9786 0.9786 
   Space Group  P212121 P32 
   Cell  Dimensions a,b,c (Å)   72.2, 79.7, 176.0 73.1, 73.1, 136.0 
   Resolution Range (Å)a  25.0-1.80 (1.84-1.80) 25.0-2.50 (2.57-2.50) 
   Rmerge  (%)
a  6.00 (41.80) 5.90 (43.20) 
   I/I a  31.27 (5.25) 18.60 (2.40) 
   Completeness (%)a  94.50 (100.0) 91.50 (87.0) 
Unique Reflections  89,438 25,850 
   Redundancya  13.70 (10.60) 5.30 (3.10) 
Refinement & Validationb    
   No. of Reflections  84,616 24,508 
   No. of Atoms  5891 5347 
      Protein Atoms  5347 5182 
      Ligand Atoms   133 4 
      Solvent Atoms  411 161 
   Rwork/Rfree
 c  18.9/ 21.4 20.7/24.6 
   B-factors (Å2)     
      Overall  20.5 39.0 
      Protein  19.7 39.5 
      Ligands   33.5 46.9 
      Waters  26.3 21.0 
   Root Mean Square Deviation    
      Bond Length (Å)  0.015 0.013 
      Bond Angles (°)  1.43 1.49 
   MolProbity Scores    
      Clashscore (all atoms)d  6.85 (90th percentile N=837) 7.94 (98th percentile N=271) 
      Molprobity Score  1.41 (96th percentile N=11444) 2.23 (89th percentile N=6960) 
      Resolution Range (Å)  1.80 ± 0.25 2.50 ± 0.25 
   Ramachandran    
      Favored (%)  98.5 95.7 
      Allowed  (%)  1.5 4.3 
      Outliers (%)  0 0 
 
a 
Values in parentheses correspond to the highest-resolution shell. 
b 
Structures were refined in 
Refmac [42] using isotropic temperature-factor refinement  
c
 Rwork = Σ ||Fo|-|Fc|| / Σ |Fo| ; Rfree = 5% of 
the total reflections.  
d 












Figure 3.6: Structure of JMJD2D apoenzyme at 2.5Å resolution. The secondary structure 
elements are defined as: α-helices; β-sheets; 310-310 helices. Cyan and gray spheres represent 
Ni(II) and Zn(II) respectively.   
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The JmjC domain (residues 146-312) of the enzyme adopts a β-barrel fold that is highly 
homologous to the structures of other JMJD2 KDMs [33-35, 49]. The C-terminal region of the 
enzyme (312-342) harbors a Zn-binding motif composed of residues His244, Cys238, Cys310 
and Cys312 (Figure 3.6), a structural feature conserved throughout the JMJD2 family. The 
overall structure and domains of JMJD2D are very similar to JMJD2A and JMJD2C with an 
RMSD Cα (261 atoms) of ~ 0.4Å (Figure 3.7).  
 
Structure of the JMJD2D•2-OG•H3K9me3 Complex  
The overall structure of the JMJD2D ternary complex and apoenzyme were very similar 
and there were no major structural changes upon peptide binding (RMSD Cα = 0.26 Å for all 
aligned Cα atoms) (Figure 3.8). Simulated annealing omit maps illustrate clear electron density 
for the co-factor 2-OG, the active site Ni(II) that is bound in the Fe(II) coordination site and 
residues 6-15 in the H3K9me3 peptide substrate (Figures 3.9 and 3.10). Prior to the solution of 
our structures, two unpublished structures of the JMJD2D catalytic domain were deposited in the 
Protein Data Bank (PDB entry: 3DXT and 3DXU) and had been cited in previous studies [49]. In 
these structures, the C-terminal region adopts an alternative conformation that is not observed in 
JMJD2A, JMJD2C, or the JMJD2D structures reported here (Figure 3.11). This alternative 
conformation is presumably stabilized by crystal packing forces as there some crystal contacts 
observed at the C-terminal region of JMJD2D (Figure 3.12). Structural alignment with the 
JMJD2D ternary complex illustrates that this alternate conformation results in steric clashes with 
the N-terminal region of the H3K9me3 substrate (Figure 3.13). In addition, Gly174, which forms 
part of the trimethyllysine binding pocket (Figure 3.11) is shifted ~12 Å out of the active site in 














Figure 3.7: Structural conservation among JMJD2 KDMs. Alignment of the apoenzyme 
structures of JMJD2A (blue), JMJD2C (yellow) and JMJD2D (purple). RMSD Cα (261 atoms)= 










Figure 3.8: Structure of the JMJD2D•2-OG•H3K9me3 ternary complex at 1.8Å resolution. 
The JmjN domain (orange), JmjC domain (pink), Mixed domain (blue) and C terminal domain 
(red) are depicted in cartoon representation with the secondary structural elements labeled. Cyan 
and gray spheres represent Ni (II) in the active site and Zn(II) in the C-terminal Zn motif, 
respectively. Stick representation of the cofactor 2-OG (black) and the substrate H3K9me3 




















Figure 3.9: Simulated annealing omit map of 2-OG and Ni(II).  Fo-Fc omit map of are 














Figure 3.10: Simulated annealing omit map of the H3K9me3 peptide. Fo-Fc omit maps are 
contoured at 2.0 σ for the H3K9me3 peptide (green). *Two conformations were observed for 
S10 and each was modeled with an occupancy of 0.5. 
‡ 
The side chain of K14 was not modeled 











                      
Figure 3.11: Comparison of the JMJD2D•2-OG•H3K9me3 structure and 3DXT. 
Superimposition of the structures JMJD2D•2-OG•H3K9me3 ternary complex (pink and green) 
and an unpublished structure of the JMJD2D catalytic domain that was previously deposited into 
the Protein Data Bank (3DXT.pdb, gray). The dark pink and black spheres represent the position 
of the active site Gly174 in the JMJD2D•2-OG•H3K9me3 and 3DXT structures, respectively. 
The positions of helices α4, α8 and α9 (denoted by black arrows) in the 3DXT structure are 
















Figure 3.12: Crystal contacts in 3DXT. The alternate C-teminal conforamtion observed in the 
3DXT structures could be stabilized by crystal contacts (yellow dashes). Residues from 


























Figure 3.13: Steric clashes in the 3DXT structure. Docking of the H3K9me3 peptide (green 
carbons) into the 3DXT structure (gray) based on its superimposition with the JMJD2D ternary 
complex illustrates steric clashes (denoted by red dashes) between A7 in the peptide and Val317 
and Thr318 in the 3DXT structure. The clashes are a consequence of the alternate conformation 





conformation is incompatible for trimethyllysine recognition and demethylation. 
In the active site of JMJD2D, Ni(II) occupies the Fe(II) binding site and is coordinated by 
His192, Glu194, and His280 (Figure A.3 in Appendix A). The methyl groups of K9me3 in the 
H3 peptide are coordinated by a network of CH•••O hydrogen bonds to residues Tyr181, Glu194 
and Gly174 in JMJD2D. This binding mode is conserved in JMJD2A, with the exception that 
Ala292 in JMJD2D is substituted by Ser288 in JMJD2A (Figure A.3 in Appendix A) [34]. The 
H3K9me3 peptide adopts a “W”-shaped conformation with two sharp bends when bound in the 
histone binding cleft of JMJD2D, analogous to the H3K9me3 binding mode observed in 
JMJD2A [34, 35]. The first bend occurs at K9me3 and deposits the trimethyllysine substrate into 
a narrow channel leading to the active site, whereas the second bend at T11 positions the 
threonyl side chain into a shallow pocket adjacent to the active site (Figure 3.8).  
 
Interactions of JMJD2D with Substrate H3K9me3     
 A combination of main chain and side chain hydrogen bonds and van der Waals contacts 
between the H3K9me3 peptide and JMJD2D facilitate optimal recognition of the substrate 
(Figure 3.14). Most of the side chain interactions occur close to the demethylation site i.e. K9. At 
the -1 position, R8 is recognized by an intricate network of hydrogen bonds to Asp135 and 
Tyr179 in JMJD2D. With respect to residues in the C-terminal half of the H3K9me3 peptide, 
S10, T11 and G12, corresponding to the +1, +2 and +3 positions, adopt a bent conformation that 
enables these amino acids to bind efficiently inside a pocket adjacent to the active site. This bent 
conformation is maintained through two hydrogen bond networks: (1) S10 adopts two alternate 
side chain conformations that enable intra-peptide hydrogen bonding to either the G12 carbonyl 












Figure 3.14: Recognition of the H3K9me3 peptide by JMJD2D. Interactions between the 
H3K9me3 peptide substrate (green) and JMJD2D (pink) showing intra-peptide and enzyme-




side chains of T11 and Asp139 in JMJD2D (Figure 3.14). In addition to these side chain 
interactions a few main chain interactions are also formed between JMJD2D and the peptide. 
Hydrogen bonds between the carbonyl oxygen of Glu173 and backbone nitrogen of K9 and 
between side chain hydroxyl group of Tyr179 and carbonyl oxygen of K9 enable efficient 
positioning of the K9me3 side chain into the deep acidic pocket that leads into the active site. At 
the C- terminal region, a hydrogen bond is formed between the backbone nitrogen of His90 and 
carbonyl oxygen of G13. In summary, a number of main chain and side chain peptide 
interactions enable efficient recognition of the H3K9me3 site by JMJD2D.   
 
DISCUSSION 
The crystal structure of the ternary complex offers insights into how the H3K9me3 site is 
efficiently recognized by JMJD2D. The apoenzyme structure reveals that JMJD2D does not 
undergo any major structural changes to accommodate the histone substrate consistent with what 
has been reported with JMJD2A [34, 35]. The structure of the catalytic domain of JMJD2D is 
very similar to that of the other human JMJD2 homologs such as JMJD2A and JMJD2C which 
can demethylate the H3K9me3 site. The JmjC domain structure is also well conserved between 
JMJD2D and the yeast JmjC KDM, Rph1 with an RMSD of 0.8 Å [50]. Rph1 is exhibits similar 
substrate specificities to the JMJD2 family wherein it can demethylate both H3K9me3 and 
H3K36me3 [50, 51]. Although there is no structural data of an Rph1-substrate complex, some of 
the residues involved in efficient recognition of H3K9me3, such as Asp139 in JMJD2D (Asp135 
in JMJD2A) and Tyr179 in JMJD2D (Tyr175 in JMJD2A) are conserved in Rph1 indicating 
potential similarities in the mode of substrate recognition. 
JMJD2D  engages in a number of interactions with the H3K9me3 peptide, most of them 
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being proximal to the K9me3 site. Many of these enzyme-peptide interactions are also conserved 
in the JMJD2A•H3K9me3 peptide complex, but upon close inspection, several subtle, albeit 
significant differences were noticed in the H3K9me3 binding modes between JMJD2D and 
JMJD2A, suggesting differences in recognition of this site (Chapter 4). In addition, using the 
structures of JMJD2D and a JMJD2A•H3K36me3 complex [33], we delineated the molecular 
basis for discrimination against the H3K36me3 site by JMJD2D (Chapter 4). 
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METHYLATION SITE SPECIFICITY STUDIES-DIFFERNTIAL SPECIFICITY OF 
JMJD2D AND JMJD2A 
 
Functional diversity within the JMJD2 family of demethylases has been attributed in part 
to their differential substrate specificities. Despite their high sequence identity (>75%,  Figure 
3.1 in Chapter 3) and structural homology, members of the JMJD2 family exhibit striking 
differences in their substrate specificities with respect to the recognition of H3K36me3.  Most 
JMJD2 KDMs can efficiently demethylate H3K9me3 and H3K36me3, with the exception of 
JMJD2D which is an H3K9me2/3-specific demethylase [1, 2]. To delineate the molecular 
mechanisms of site specific demethylation in the JMJD2 family, we determined the crystal 
structure of JMJD2D in the apoenzyme form and in complex with its cognate H3K9me3 
substrate (Chapter 3). Using this structural data, we performed structural comparisons with 
JMJD2A and biochemical analysis with an array of mutant histone peptides to understand how 
these enzymes recognized H3K9me3. We also analyzed the role of T11 phosphorylation on 
H3K9me3 demethylation by the JMJD2 enzymes. To understand why JMJD2D lacked 
specificity for the H3K36me3 site, we performed docking studies using JMJD2A•H3K36me3 
and our JMJD2D structures. Lastly, we corroborated our docking predictions by performing a 
series of biochemical analysis on hybrid peptide substrates. These studies furnish a clear 
understanding of how JMJD2 enzymes recognize the H3K9me3 site and the molecular basis by 
which JMJD2D occludes the H3K36me3 site.  
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MATERIALS AND METHODS 
Protein Expression and Purification 
For demethylase assays, the catalytic domains of JMJD2A (residues 1-350),  JMJD2C 
(residues 1-350) and JMJD2D (residues 12-342) were expressed and purified using the Strep-
Tactin affinity method combined with an S200 column purification as described in Chapter 2. As 
JMJD2B (residues 9-357) was unstable after gel filtration chromatography, enzyme assays were 
performed with concentrated fractions of the enzyme from the Strep-Tactin column. Protein 
concentration was determined by their absorbance at 280 nm in 6.0 M guanidinium chloride and 
100 mM HEPES (pH 7.5) [extinction coefficients were calculated using ExPASy ProtParam 


















Protein samples were flash frozen in liquid N2 and stored at -80º C.  
 
Histone Substrate Peptides 
Methylated histone H3 peptide substrates used in the kinetic analyses of JMJD2A and 
JMJD2D were purchased from Anaspec Inc., and were purified with a chloride counter ion. The 
peptide were dissolved in MilliQ water , vortexed for 10 sec and the peptide vials were 
centrifuged at 1500 rpm for 2 min. This was done to ensure accurate peptide concentration, 
particularly for peptides weighed by net peptide content.  Peptide concentrations were quantified 
by amino acid analysis, with the exception of peptides containing a tyrosine, whose 
concentrations were measured by their absorbance at 274 nm (Molar extinction coefficient of 




). The sequences of the peptides used in kinetic experiments 
are listed in Table 4.1. 
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FDH-Coupled Demethylase Assay 
KDM activity was measured using the FDH-coupled demethylase assay as described in 
Chapter 2. All peptides were dissolved in Milli-Q water. The assay was initiated by the addition 
of 1.0 mM 2-OG and a variable concentration of peptide substrate into the assay cocktail 
containing 50 mM HEPES buffer (pH 7.5), 50 mM NaCl, 50 µM (NH4)2Fe(SO4)2, 1.0 mM L-
ascorbic acid, 1.0 mM NAD
+
, 0.1 µM recombinant FDH and 1.0 µM JMJD2 KDM. NADH 
fluorescence was continuously monitored (ex 340/em 490) at 30 sec intervals using a Sapphire 2 
microplate reader. Kinetic data were processed using GraphPad Prism.  
 
Molecular Docking of JMJD2D and H3K36me3 
 Docking analysis was performed using PyMOL. The PDB files of JMJD2A•H3K36me3 
complex structure (PDB ID: 2P5B) and that of JMJD2D•H3K9me3 were modified as follows: 
since both structures contained two molecules in the asymmetric unit, one of the molecules was 
removed from the PDB file using the Text Wrangler software. In addition, water, other solvent 
and cofactor atoms were removed. Using these modified PDB files, the align function in PyMOL 
was used to align the two structures. This resulted in a close alignment of JMJD2A and JMJD2D 
protein molecules (RMSD Cα (261 atoms) = 0.42Å). The trimethyllysine side-chains of the 
H3K9me3 peptide from the JMJD2D structure and the H3K36me3 peptide from the JMJD2A 
structures were nearly superimposed suggesting that the H3K36me3 peptide was modeled in the 
correct direction. To analyze the JMJD2D•H3K36me3 docked structure using MOLPROBITY, 
the PDB files were generated as follows: from the previous alignment, all atoms of JMJD2A and 
H3K9me3 were removed. The resultant PDB file contained the coordinates of JMJD2D and the 





























Peptides with the H3K9me3 site were synthesized with C-terminal amide groups, whereas 
peptides encompassing the H3K36me3 site were synthesized with N-terminal acetyl and C-
terminal amide groups. 
 
1 H3K9me3 ARTKQTARK(me3)STGGKA-amide 
2 H3K9me3_R8A ARTKQTAAK(me3)STGGKA-amide 
3 H3K9me3_S10A ARTKQTARK(me3)ATGGKA-amide 
4 H3K9me3_T11A ARTKQTARK(me3)SAGGKA-amide 
5 H3K9me3_S10A_T11A ARTKQTARK(me3)AAGGKA-amide 
6 H3K9me3_T11S ARTKQTARK(me3)SSGGKA-amide 
7 H3K9me3T11ph ARTKQTARK(me3)ST(ph)GGKA-amide 
8 H3K36me3 acetyl-SAPATGGVK(me3)KPHRYR-amide 
9 H3K36me3_R40A acetyl-SAPATGGVK(me3)KPHAYR-amide 
10 H3K9K36me3 ARTKQTARK(me3)KPHRYR-amide 
11 H3K36K9me3 acetyl-SAPATGGVK(me3)STGGKA-amide 
12 H3K36K9me3_V35R acetyl-SAPATGGRK(me3)STGGKA-amide 
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were rendered using PyMOL (Schrodinger, LLC) and the electrostatic surface was calculated 
using the Adaptive Poisson-Boltzmann Solver (APBS) plugin for PyMOL (Baker et al., 2001).  
 
RESULTS 
Comparison of H3K9me3 Recognition by JMJD2D and JMJD2A 
 The H3K9me3 binding mode appears to be conserved between JMJD2A and JMJD2D, 
consistent with the similar catalytic efficiencies (kcat/Km values) they display toward an 
H3K9me3 peptide substrate (Table 2.4 from Chapter 2). The recognition of H3K9me3 site by 
JMJD2A and JMJD2D involves hydrogen bonds or van der Waals contacts to residues R8, S10, 
T11 and G12 at the -1, +1, +2 and +3 positions in the H3K9 sequence (Figure 3.14 from Chapter 
3). We first examined the interactions involving R8 recognition that were not characterized in 
previous studies involving JMJD2 enzymes [3-5]. R8 corresponds to the -1 position in the 
peptide sequence relative to K9 and is recognized by an intricate network of hydrogen bonds to 
Asp135 and Tyr179 in JMJD2D and to Glu169 in JMJD2A (Figure 4.1). Mutation of R8 to 
alanine (R8A) in the H3K9me3 peptide resulted in 6-10 fold decreases in the catalytic 
efficiencies compared to the demethylation of the WT peptide for both enzymes (Table 4.2 and 
Figure 4.1). These decreases were predominantly due to an increase in the Km values for the 
H3K9me3_R8A peptide that is indicative of impaired binding to JMJD2A and JMJD2D, 
highlighting the importance of the interactions at the -1 position in the overall recognition of 
H3K9me3. The residues that interact with R8 are conserved among all JMJD2 homologs (Figure 
4.2), implying that recognition of R8 in the -1 position of the H3K9 sequence is a universal mode 
of recognition among the JMJD2 KDMs.  
With respect to residues in the C-terminal half of the H3K9me3 peptide, S10, T11 and 







Figure 4.1: Recognition of R8 in the H3K9me3 substrate.  (A) JMJD2D•H3K9me3 complex 
and (B) JMJD2A•H3K9me3 complex. The catalytic efficiencies (kcat/Km values) of the WT 

















































































































































Figure 4.2: Conservation of R8-recognizing residues. Alignment of the amino acid sequence 
of the human JMJD2 homologs illustrating the sequence identity of residues involved in the 
recognition of R8 in the H3K9me3 substrate (●). Identical residues are depicted with black 
background and homologous residues are shown in gray background.   
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amino acids to bind efficiently inside a pocket adjacent to the active site, as observed in JMJD2A  
(Figure 4.3) [3, 5]. As described in Chapter 3, in JMJD2D, the bent conformation in the C-
terminal half of H3K9me3 is maintained through two hydrogen bond networks: (1) S10 adopts 
two alternate side chain conformations that enable intra-peptide hydrogen bonding to either the 
G12 carbonyl oxygen and amide nitrogen or to the R8 carbonyl oxygen and (2) a hydrogen bond 
between the side chains of T11 and Asp139 in JMJD2D (Figure 4.3A). Mutation of S10 to 
alanine (S10A) or T11 to alanine (T11A) resulted in only a two-fold reduction in the catalytic 
efficiency compared to the WT peptide with JMJD2D (Table 4.2 and Figure 4.3A). A double 
S10A_T11A mutation however, resulted in a six-fold decrease in catalytic efficiency, indicating 
that a combination of interactions to S10 and T11 is important for optimal recognition of the 
H3K9me3 site by JMJD2D. Interestingly, this decrease was predominantly due to a decrease in 
the kcat values while the Km values were identical to the individual S10A and T11A mutations 
(Table 4.2). This suggests that the bent conformation at the C terminus might play an important 
role in JMJD2D catalysis, potentially by enabling proper positioning of the substrate K9me3 into 
the active site. The mode of recognition of S10 and T11 by JMJD2D starkly contrasts the 
recognition of these residues by JMJD2A. In a JMJD2A•H3K9me3 complex, the C-terminal bent 
conformation in the peptide is stabilized only by intra-peptide hydrogen bonds between the side 
chain hydroxyl group of S10 and backbone oxygen and nitrogen atoms of G12, whereas T11 is 
rotated away from Asp135 and does not form hydrogen bonds with JMJD2A, unlike in JMJD2D 
(Figure  4.3B). An S10A mutation abrogates H3K9me3 recognition by JMJD2A with an ~12- 
fold decrease in catalytic efficiency compared to the wild type (WT) H3K9me3 peptide (Table 
4.2 and Figure 4.3B). This decrease was primarily due to an eight-fold increase in the Km value 









Figure 4.3: Recognition of S10 and T11 in the H3K9me3 substrate. (A) JMJD2D•H3K9me3 
complex and (B) JMJD2A•H3K9me3 complex.  kcat/Km values for WT H3K9me3, 
H3K9me3_S10A, H3K9me3_T11A and H3K9me3_S10A_T11A peptide substrates are shown as 




other hand, a T11A mutation did not affect recognition of the H3K9me3 site, consistent with the 
lack of hydrogen bonding between T11 and JMJD2A (Table 4.2 and Figure 4.3B). Interestingly, 
a T11S mutation resulted in a 6-10 fold increase in the kcat/Km of JMJD2A and JMJD2D 
compared to WT H3K9me3 (Figure 4.4), primarily due to a decrease in the Km values for 
JMJD2A and JMJD2D (Table 4.2). The presence of a serine residue at the +2 position, 
corresponding to H3T11 may be more amenable to hydrogen bonding to the carboxylate group 
of Asp139 in JMJD2D (Asp135 in JMJD2A) compared to the bulkier threonyl side chain that has 
more limited conformational freedom due to steric constraints within +2 binding pocket in the 
enzymes’ substrate binding cleft. In summary, the structural and kinetic data illustrate that R8 is 
recognized in a highly conserved manner in both JMJD2A and JMJD2D and highlight major 
variations in the recognition of S10 and T11 by these enzymes, despite the homology of the 
H3K9me3 peptide conformation and structural conservation of the +1 and +2 binding pockets in 
these homologs. 
 
Role of H3T11ph in the Recognition of H3K9me3 by JMJD2 KDMs 
 Previous studies have demonstrated that other post-translational modifications in the 
residues flanking H3K9me3 can influence demethylation by JMJD2 KDMs. For example, 
phosphorylation of S10 (S10ph) has been reported to abolish H3K9me3 demethylation by 
JMJD2A [5], consistent with the importance of this residue in H3K9me3 recognition. 
Correlatively, protein-kinase-C-related kinase 1 (PRK1) and the cell cycle checkpoint kinase 
(Chk1) have been shown to phosphorylate T11 in histone H3 (H3T11ph), a modification that has 
been implicated in regulating androgen receptor (AR) signaling and DNA damage response [6, 

















Figure 4.4:  Activity of JMJD2A and JMJD2D toward an H3K9me3_T11S peptide. 
Comparison of the kcat/Km values of JMJD2A and JMJD2D with WT H3K9me3 and an 
H3K9me3_T11S peptide substrate showing that substitution of threonine at the +2 position with 




H3K9me3 by JMJD2C and promote the upregulation of AR target genes [6]. Contrary to this 
finding, we observed that JMJD2A, JMJD2B, JMJD2C and JMJD2D are inactive toward an 
H3K9me3T11ph peptide, indicating T11ph abrogates H3K9me3 demethylation by JMJD2 
KDMs (Figure 4.5). When we modeled a phosphorylated threonine residue in the +2 binding 
pocket of JMJD2D, we observed a number of steric clashes with Ala138, Tyr181 and the 
potential rotation of the threonyl sidechain could result in clashes with Tyr136, Leu75, His90 and 
Phe189 (Figure 4.6). Furthermore, the presence of the invariant Asp139 less than 2Å from T11ph 
could potentially result in electrostatic repulsion (Figure 4.6).  In conclusion, our structural and 
biochemical analysis illustrate that the dimensions of the +2 binding pocket in JMJD2 enzymes 
sterically and electrostatically preclude the binding of T11ph in the H3K9me3 substrate. 
 
Mode of H3K36me3 Occlusion by JMJD2D 
 Previous studies have shown that JMJD2A and JMJD2C exhibit dual specificity for both 
H3K9me3 and H3K36me3 [2]. Our kinetic analysis on JMJD2B revealed that it is also specific 
for both H3K9me3 and H3K36me3 (Table 4.3). JMJD2D is the only member of the human 
JMJD2 KDMs that is specific for H3K9me3 and cannot recognize the H3K36me3 site. To 
understand the molecular determinants underlying this varied specificity, we performed docking 
studies with a previously solved structure of a JMJD2A•N-oxalylyglycine•H3K36me3 complex 
[1]  with the structure of our JMJD2D ternary complex. First, we identified several regions 
flanking the substrate binding cleft that differ in either sequence or structural conservation 
between the enzymes (Figure 4.7). Second, our docking studies revealed severe steric and H39 
and R40 in the H3K36me3 peptide and His90 and Leu75 in JMJD2D, respectively (Figure 4.8). 
















Figure 4.5: Activity of JMJD2 enzymes for an H3K9me3T11ph peptide. Comparison of the 
initial velocities of JMJD2A, JMJD2C and JMJD2D with WT H3K9me3 and H3K9me3T11ph 
















Figure 4.6: T11ph modeled in the JMJD2D peptide binding cleft. The T11 binding pocket in 
JMJD2D (pink) with a T11ph residue (green and orange) depicting electrostatic repulsion with 








Table 4.3: Kinetic Analysis of JMJD2 KDMs  
 
Kinetic Parameters – H3K9me3 
 Km µM kcat min
-1







JMJD2A 56 ± 9  1.7 ± 0.1 31 ± 4 
JMJD2B 28 ± 3 1.2 ± 0.1 42 ± 3  
JMJD2C 25 ± 1 0.66 ± 0.01 26 ± 1 
JMJD2D 53 ± 9 2.3 ± 0.2 45 ± 4 
Kinetic Parameters – H3K36me3 
 Km µM kcat min
-1







JMJD2A 130 ± 6 1.2 ± 0.2 9.3 ± 1.4 
JMJD2B 98 ± 16 0.33 ± 0.02 3.4 ± 0.4 
JMJD2C 140 ± 31 0.23 ± 0.02 1.7 ± 0.2 
JMJD2D N.A. N.A. N.A. 
 




















Figure 4.7: JMJD2D docked with the H3K36me3 peptide. Surface representation of JMJD2D 
(pink) containing the docked H3K36me3 peptide (gray sticks). Purple patches highlight regions 















Figure 4.8: Occlusion of H39 and R40 by JMJD2D. Steric clashes between H39 and R40 in 
H3K36me3 (gray) and Asp139, Leu75 and His90 in JMJD2D (pink) are shown as red dashes.  
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accommodate H39 and R40 through van der Waals interactions (Figure 4.9). Further, Asp135 in 
JMJD2A forms a salt bridge with R40, an interaction that is pivotal for efficient demethylation of 
H3K36me3, as illustrated by the impaired demethylation of an H3K36me3_R40A peptide (Table 
4.2 and Figure 4.10). Corroborating these observations, mutation of Ile71 to a leucine (I71L) 
resulted in a 16-fold decrease in catalytic efficiency of JMJD2A toward H3K36me3, whereas the 
activity toward H3K9me3 remained unperturbed (Figure 4.11 and Table 4.4). Additionally, the 
C-terminus of the H3K36me3 peptide harbors a positively charged cluster comprising H39, R40 
and R42 that is juxtaposed to a positively charged patch on the surface of JMJD2D that includes 
Lys91 and Lys92, which may further preclude H3K36me3 binding via electrostatic repulsion 
(Figure 4.12A). In JMJD2A, Lys91 and Lys92 correspond to neutral amino acids Ile87 and 
Gln88 (Figure 4.12B).  
 In addition to accommodating the H3K36me3 substrate without steric or electrostatic 
clashes, JMJD2A engages in several interactions along the length of the H3K36me3 peptide that 
promote substrate recognition [1]. At the -1 position of the H3K36me3 site, the amide nitrogen 
of V35 engages in a hydrogen bond with the backbone carbonyl oxygen of Asp311 in the loop 
linking helices α9 and α10 in the C-terminal region of JMJD2A (Figure 4.13). This interaction 
facilitates the proper positioning of K36me3 substrate into the active site [1]. Both the sequence 
and conformation of the loop that interacts with V35 vary substantially between JMJD2A and 
JMJD2D. In JMJD2A, residues Arg309, Lys310, Asp311, and Met312 (RKDM motif) form a 
broad ‘U’-shaped loop that bends sharply near the peptide-binding cleft, positioning the carbonyl 
oxygen of Asp311 for hydrogen bonding to the V35 amide (Figure 4.13). In JMJD2D, this loop, 
consisting of residues Gly313, Glu314, Ala315, Arg316 (GEAR motif), is oriented away from 
















Figure 4.9: Favorable recognition of H39 and R40 by JMJD2A. R40 in H3K36me3 (gray) is 
recognized by a salt bridge (black dashes) with Asp135 in JMJD2A (blue) [PDB entry: 2P5B]. 

















Figure 4.10: Activity of JMJD2A for an H3K36me3_R40A peptide.  Mutation of R40 in 
histone H3 to alanine results in a fourfold decrease in catalytic efficiency of JMJD2A compared 












Figure 4.11: Kinetic analysis of JMJD2A_I71L. This mutation results in a 16-fold reduction in 
catalytic efficiency for H3K36me3 compared to WT JMJD2A (Table 4.4). In contrast, the 





































JMJD2A_WT 1.7 ± 0.1 56 ± 9 31 ± 4 
JMJD2A_I71L 1.3 ± 0.1 43 ± 6 31 ± 5 
Kinetic Parameters-H3K36me3 
JMJD2A_WT 1.2 ± 0.2 130 ± 6 9.3 ± 1.4 








Figure 4.12: Electrostatic surface representations of JMJD2D (A) and JMJD2A (B). 
Electrostatic potential is contoured from +3 kbT•e 
-1
 (blue) to -3 kbT•e 
-1
 (red). The H3K36me3 
peptide (in A and B) is depicted as gray cartoon with the C-terminal basic residues H39, R40 and 
R42 represented in stick form (black). Yellow arrows refer to the positively charged regions in 











Figure 4.13: Loss of hydrogen bonding between JMJD2D and H3K36me3. Interaction 
between Asp311 in JMJD2A (blue) and V35 in H3K36me3 (gray) is shown as black dashes. The 
corresponding residue, Arg316 (pink), in JMJD2D is unable to form this hydrogen bond due to 




bonding to V35 in histone H3. Collectively, the structural comparisons between JMJD2A and 
JMJD2D combined with the JMJD2D•H3K36me3 docking analysis suggest that the loss of 
productive enzyme-substrate interactions coupled with multiple steric and electrostatic clashes 
occludes the recognition of the H3K36me3 site by JMJD2D.   
 
Activity of JMJD2D and JMJD2A Toward Hybrid Peptide Substrates 
 Biochemical analysis of JMJD2D mutants, based on sequence comparison with JMJD2A 
revealed that individual point mutations in the substrate binding cleft were not sufficient to 
render JMJD2D with H3K36me3 demethylase activity and clustered mutations significantly 
diminished enzyme stability (Table 4.5). Hence, to substantiate our docking analysis, we assayed 
the catalytic activity of JMJD2D with hybrid peptide substrates bearing the N-terminal and C-
terminal halves of the H3K9 and H3K36 methylation sites (Figure 4.14). When assayed with a 
peptide composed of the N-terminal half of the H3K9 site and the C-terminal half of the H3K36 
site (H3K9K36me3), JMJD2D exhibited no appreciable activity, consistent with that observed 
for the H3K36me3 peptide (Figure 4.15). In contrast, JMJD2D displayed a substantial increase in 
its catalytic efficiency toward an H3K36K9me3 peptide composed of the N- and C-termini of 
H3K36 and H3K9 sites, respectively (Figure 4.15). These results corroborate our docking 
studies, indicating that the residues C-terminal to K36 in histone H3 are primarily responsible for 
the discrimination of JMJD2D against this site. Although JMJD2D was capable of demethylating 
the H3K36K9me3 hybrid peptide, its catalytic efficiency toward this substrate was relatively 
weak compared to that of the WT H3K9me3 peptide (Figure 4.15 and Table 4.2). As noted 
earlier, the loop containing the GEAR motif in JMJD2D does not adopt a conformation that is 









Table 4.5: List of mutations in JMJD2D that were tested for H3K36me3 catalytic activity 
 
Although most of the mutants were stable (with the exception of Cluster 5 and combination of 
cluster 1-5 mutant), they did not exhibit any appreciable increase in catalytic activity for 











To relieve steric clash with R40 of 
H3K36me3 substrate 
H90N 
To relieve steric clash with H39 of 
H3K36me3 substrate 
Cluster 1: C168S; V171T; F319I 
To relieve minor steric clashes at residues 
N-terminal to H3K36me3 
Cluster 2: L75I; H90N 
To relieve major steric clashes at residues 
C-terminal to H3K36me3 
Cluster 3: K91I; K92Q 
To relieve electrostatic clashes at residues 
C-terminal to H3K36me3 
Cluster 4: L75I; H90N; K91I;K92Q 
To relieve steric and electrostatic clashes at 
residues C-terminal to H3K36me3 
Cluster 5: G313R;E314K;A315D;R316M 
To introduce hydrogen bond at the -1 
position of H3K36me3 
L75I; H90N;K91I;K92Q;C168S;V171T; 
G313R;E314K;A315D;R316M;F319I 











Figure 4.14: Hybrid peptides between H3K9me3 and H3K36me3. Amino acid sequences of 

















interaction at the -1 position of the demethylation site, V35 was mutated to an arginine (V35R) 
to mimic the interactions of R8 in the H3K9me3 peptide with JMJD2A and JMJD2D (Figure 
4.1A and 4.16). When assayed with the H3K36K9me3_V35R peptide, JMJD2D displayed a 
tenfold increase in the kcat/Km compared to the H3K36K9me3 hybrid substrate (Figure 4.15 and 
Table 4.2).  
To complement these results, we next analyzed the kinetic parameters of JMJD2A using 
the H3 hybrid peptides. Consistent with JMJD2D, JMJD2A was inactive toward the 
H3K9K36me3 peptide, indicating the residues preceding K36 in histone H3 are essential for 
substrate recognition (Figure 4.17 and Table 4.2). Unexpectedly, when JMJD2A was assayed 
with the H3K36K9me3 hybrid peptide, we observed a four-fold reduction in the kcat/Km 
compared to WT H3K36me3 (Figure 4.17 and Table 4.2). The decrease in catalytic efficiency 
for the H3K36K9me3 peptide may have been a consequence of the loss of the salt bridge 
interaction between R40 in histone H3 and Asp135 in JMJD2A (Figure 4.9), as an R40A 
mutation in the H3K36me3 peptide impairs the catalytic efficiency of JMJD2A by fourfold 
(Figure 4.10 and Table 4.2). Conversely, JMJD2A exhibited a sevenfold increase in its catalytic 
efficiency when assayed with the H3K36K9me3_V35R peptide compared to WT H3K36me3 
(Figure 4.17 and Table 4.2). This increase in activity presumably reflects a compensatory effect 
in which the V35R mutation enhances interactions with JMJD2A through hydrogen bonding in 
the -1 position, as observed for R8 in the H3K9me3 site (Figure 4.1B). This interaction would 
offset the mutation of R40 to glycine in the H3K36K9me3 hybrid substrate (Figure 4.14) that 
abolishes a salt bridge interaction with Asp135 in the substrate binding cleft (Figures 4.9 and 
4.10). In summary, the kinetic data corroborate our structural alignment and docking analysis of 
















Figure 4.16: Rationale for the H3K36K9_V35R substrate. Overlay of the H3K9me3 (green) 

















of productive enzyme-substrate interactions contribute to the discrimination against H3K36me3 
demethylation by JMJD2D. 
 
DISCUSSION 
Mode of H3K9me3 Recognition and H3K36me3 Occlusion by JMJD2 KDMs 
Members of the JMJD2 family of KDMs have been implicated in numerous genomic and 
developmental functions [8-12]. The functional diversity within this family has been attributed in 
part to their differential substrate specificities. JMJD2A, JMJD2B and JMJD2C efficiently 
demethylate H3K9me3 and H3K36me3, whereas JMJD2D is an H3K9me2/3-specific 
demethylase. Our structural studies reveal that JMJD2A and JMJD2D employ similar modes of 
recognition of the H3K9me3 site at the -1 position through hydrogen bonding to R8 (Figure 4.1). 
However, these enzymes display unexpected differences in the recognition of residues S10 and 
T11 at the +1 and +2 positions of the H3K9me3 site, despite the overall structural homology of 
the H3K9me3 peptide binding mode and the S10-T11 binding clefts (Figure 4.3). S10 is pivotal 
for the recognition of H3K9me3 site by JMJD2A, whereas in JMJD2D, this requirement is more 
flexible owing to a compensatory interaction formed between T11 and Asp139 in JMJD2D. In 
addition, our structural and kinetic results also illustrate that phosphorylation of T11 impedes 
demethylation of H3K9me3 by JMJD2D KDMs, contrary to previous reports [6]. These findings 
correlate with prior studies illustrating that S10ph abrogates demethylation of H3K9me3 by 
JMJD2A [5] and are consistent with the overall acidic character of the S10-T11 binding clefts in 
JMJD2A and JMJD2D (Figure 4.6) that are electrostatically incompatible with the binding of 
S10ph and T11ph in histone H3. 
Our structural and biochemical studies highlight key interactions at the -1, +1, +2 and +3 
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positions in the H3K9me3 sequence that are important for substrate recognition by JMJD2A and 
JMJD2D.  These ‘signature’ residues are also conserved in other known substrates of JMJD2 
KDMs, most notably K26me3 of linker histone H1.4 (H1.4K26me3) that has shown to be 
efficiently demethylated by all members of the JMJD2 family [13]. This site bears strong 
sequence similarity to H3K9me3, including R25 (at the -1 position), S27 (at the +1 position), 
A28 (at the +2 position) and G29 (at the +3 position), suggesting a conserved mode of 
recognition of these sites by the JMJD2 family (Figure 4.18). In contrast to H3K9me3 and 
H1.4K26me3, JMJD2 homologs display distinct preferences for H3K36me3, which is efficiently 
demethylated by JMJD2A, JMJD2B and JMJD2C but is not recognized by JMJD2D. The 
structural comparisons of JMJD2A and JMJD2D and docking studies reveal that steric and 
electrostatic clashes combined with lack of productive interactions with the H3K36me3 substrate 
contribute to the inability of JMJD2D to demethylate this site. Consistent with these findings, the 
residues that can favorably accommodate H3K36me3 recognition, are conserved among 
JMJD2A, JMJD2B, and JMJD2C, but are divergent in JMJD2D (Figure 4.19).  
 
Comparing the JMJD2 and UTX Enzyme Families 
Despite their ability to demethylate H3K9me3, JMJD2 KDMs are inactive toward the 
H3K27me3, a methylation site that mediates Polycomb group silencing [14-16]. Although the 
H3K9 and H3K27 sequences harbor a conserved ARKS motif (where K is the methylated 
lysine), sequence variations outside this ARKS motif, such as P30 in the +3 position, preclude 
recognition of H3K27me3 site by the JMJD2 enzymes [1, 3, 5]. A recently reported crystal 
structure of the H3K27me3-specific KDM UTX bound to an H3K27me3 peptide illustrates key 












Figure 4.18: Similarities in the H3K9me3 and H1.4K26me3 sites. Alignment of the amino 
acid sequences of H3K9me3 and H1.4K26me3 illustrating the sequence identity at the -2,-1,+1 
and +3 positions of these methylation sites. Both sites have been reported to be demethylated by 













JMJD2A          ----MASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPR 56 
JMJD2B          ---MGSEDHGAQNPSCKIMTFRPTMEEFKDFNKYVAYIESQGAHRAGLAKIIPPKEWKPR 57 
JMJD2C          --MEVAEVESPLNPSCKIMTFRPSMEEFREFNKYLAYMESKGAHRAGLAKVIPPKEWKPR 58 
JMJD2D          METMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKAR 60 
            
JMJD2A          ASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEE 116 
JMJD2B          QTYDDIDDVVIPAPIQQVVTGQSGLFTQYNIQKKAMTVGEYRRLANSEKYCTPRHQDFDD 117 
JMJD2C          QCYDDIDNLLIPAPIQQMVTGQSGLFTQYNIQKKAMTVKEFRQLANSGKYCTPRYLDYED 118 
JMJD2D          ETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFED 120 
 
JMJD2A          LERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYL 176 
JMJD2B          LERKYWKNLTFVSPIYGADISGSLYDDDVAQWNIGSLRTILDMVERECGTIIEGVNTPYL 177 
JMJD2C          LERKYWKNLTFVAPIYGADINGSIYDEGVDEWNIARLNTVLDVVEEECGISIEGVNTPYL 178 
JMJD2D          LERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYL 180 
 
JMJD2A          YFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEA 236 
JMJD2B          YFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAIGFFPGSSQGCDA 237 
JMJD2C          YFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAQGFFPSSSQGCDA 238 
JMJD2D          YFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGA 240 
 
JMJD2A          FLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRW 296 
JMJD2B          FLRHKMTLISPIILKKYGIPFSRITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATLRW 297 
JMJD2C          FLRHKMTLISPSVLKKYGIPFDKITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATVRW 298 
JMJD2D          FLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRW 300 
 
 
JMJD2A          IEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPT----PEAAE 352 
JMJD2B          IDYGKVATQCTCRKDMVKISMDVFVRILQPERYELWKQGKDLTVLDHTRPTALTSPELSS 357 
JMJD2C          IDYGKVAKLCTCRKDMVKISMDIFVRKFQPDRYQLWKQGKDIYTIDHTKPTPASTPEVKA 358 
JMJD2D          IDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDRAVVDHMEPRVPASQELST 360 
 
Figure 4.19: Divergence of residues involved in H3K36me3 discrimination. The residues in 
different domains are colored: Purple: JmjN domain; Orange: Mixed domain; Red: JmjC domain 
and Green: C-terminal domain. Residues in JMJD2A, JMJD2B and JMJD2C that permit 




JMJD2D, the H3K9me3 peptide adopts a “W”-shaped conformation that is stabilized by 
interactions from residue R8-G12 (the –1 to +3 positions) in the H3K9 site. Conversely, UTX 
binds to an H3K27me3 peptide in an extended conformation through an extensive network of 
interactions involving hydrogen bonds, hydrophobic interactions, and van der Waals contacts 
spanning residues R17 to G33 in histone H3, corresponding to the -10 to +6 positions in the 
H3K27 site (Figure 4.20). Thus, UTX requires an H3K27me3 peptide sequence approximately 
twice as long as that observed for JMJD2 KDMs with H3K9me3 for optimal substrate 
recognition. Despite these differences, these enzymes share certain similarities in their substrate 
binding modes. For example, UTX recognizes R26 in the -1 position of the H3K27me3 site 
through multiple hydrogen bonds. Moreover, an R26A mutation abolishes H3K27me3 
demethylation by UTX, in agreement with the recognition of R8 in the -1 position of H3K9me3 
site by JMJD2A and JMJD2D (Figure 4.1 and Table 4.2).  Similarly, phosphorylation of S28 at 
the +1 position abrogates demethylation of H3K27me3 by UTX, consistent with the mutual 
exclusivity of S10ph and K9me3 for demethylation by the JMJD2 enzymes. In summary, the 
differential conformations adopted by the H3K9me3 and H3K27me3 sequences facilitate distinct 
recognition modes for the demethylation of these sites by their cognate JmjC KDMs.  
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Figure 4.20: Structural alignment of the ternary complexes of JMJD2D (pink) and UTX 
(light brown). The H3K27me3 peptide adopts a more extended conformation and is recognized 
at many regions distal to K27me3. The H3K9me3 peptide, in contrast adopts tight,  ‘W’ shaped 
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SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
 
Since their discovery in 2006 [1], a large number of JmjC histone lysine demethylases 
have been biochemically, structurally and functionally characterized [2, 3]. An emerging 
common theme from these studies is that these KDMs are highly specific for various methylation 
sites and states and this specificity often dictates the biological functions of these enzymes. The 
structures of JMJD2A [4-6], JMJD2D (this study), PHF8 [7] and UTX [8] have been solved in 
complex with their cognate histone substrates, and these studies highlight specific structural 
elements in the enzymes that allow efficient recognition of their corresponding substrates. 
Interestingly, these enzymes are also structurally predisposed to occlude recognition of other 
methylation sites and are hence, highly site specific.  
The JMJD2 family of enzymes is unique because most JMJD2 KDMs exhibit dual 
specificity for two methylation sites that bear no sequence or structural similarities. JMJD2A, 
JMJD2B and JMJD2C can demethylate both H3K9me3 and H3K36me3 (Table 4.4 from Chapter 
4 and [9]). These methylation sites are linked to distinct functions: H3K9me3 is associated with 
heterochromatin and transcriptionally repressed regions. H3K36me3, on the other hand has been 
shown to associate with the elongating form of RNA Polymerase II and also play a role in gene 
splicing [3, 10-17]. Of the JMJD2 homologs, JMJD2D is an exception because, while it is highly 
efficient in recognizing H3K9me3 and H3K9me2, JMJD2D completely lacks specificity for the 
H3K36me3 site [9]. The goal of this study was to understand the molecular mechanisms by 
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which JMJD2 enzymes recognized H3K9me3 and the mechanisms of H3K36me3 occlusion by 
JMJD2D. This study provides insights into the mechanisms of site specific demethylation in the 
JMJD2 family, and the results of this study can also be used to uncover the biological functions 
of these enzymes- particularly those that pertain to H3K36me3 demethylation, which is not fully 
understood. In addition, the identification of mutant substrates that bind with higher affinity than 
the cognate H3K9me3 (eg: H3K9me3_T11S) substrate will be highly valuable in the design of 
peptido-mimetic inhibitors for a number of JMJD2 KDMs that are overexpressed in gastric, 
breast and prostate cancers and in certain heart diseases [18-34].  
 
Methods for Purifying and Assaying Fe(II)-dependent Dioxygenases  
 In order to biochemically characterize the JMJD2 enzymes, we developed a purification 
and assay scheme that would aid in the accurate measurement of kinetic parameters. A highly 
overlooked fact in the field is that all JmjC enzymes are Fe(II) dependent metalloenzymes and 
are highly susceptible to transition state metal inhibition. To circumvent this metal inhibition 
caused by the use of metal affinity columns, we adopted a metal-free Strep-Tactin purification 
system (Chapter 2). Our two step Strep-Tactin-Superdex 200 purification scheme resulted in 
highly pure enzyme and metal analysis of these samples revealed less than 15% total metal 
content (Table 2.3 from Chapter 2). We also optimized the FDH-coupled demethylase assay 
including the source and concentration of all reagents and substrate peptides. When we assayed 
Strep-Tactin column purified JMJD2A and JMJD2D with the optimized assay, we measured 
turnover numbers that were 50-100 fold greater than their Ni(II) column purified counterparts 
[5]. We have used the same purification and assay scheme to characterize other JmjC enzymes 
such as UTX and JMJD3. Moreover, using this assay (in combination with mass spectrometry 
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analysis), we showed that the JmjC protein JMJD5 is not a histone demethylase as reported by 
Hsia et al [35]. These biochemical data were further supported by our JMJD5 structural studies 
[36]. The purification scheme reported in Chapter 2 is not only applicable to the various families 
of KDMs but will be useful in the biochemical characterization of other Fe(II) dependent JmjC 
enzymes including protein hydroxylases such as hypoxia-inducible factors (HIFs) and factor 
inhibiting hypoxia-inducible factor 1 (FIH-1) , RNA hydroxylases  such as tRNA wybutosine-
synthesizing enzyme 5 (TYW5) and mRNA demethylases such as Fat-mass and obesity 
associated proteins (FTO). More recently 2-OG dependent dioxygenases including the J-binding 
proteins (JBPs) and Ten-eleven translocation (TET) enzymes have garnered attention due to their 
potential roles in DNA demethylation. The JBP proteins are thymidine hydroxylases [37] 
whereas the closely related TET proteins have been reported to catalyze the hydroxylation, 
formylation and carboxylation of 5-methylcytosine [38-40]. While most of the biochemical 
studies on TET enzymes have been performed using FLAG and HA affinity tags [38, 40], kinetic 
studies on the JBP enzymes were done using metal affinity columns [37]. These kinetic analyses 
may not reflect the optimal catalytic activity of the JBP enzymes due to potential metal 
contamination in the active site. In these cases, use of Strep(II)-tagged dioxygenases coupled 
with the Strep-Tactin affinity purification could yield highly pure apoenzymes that can be 
reconstituted with Fe(II) in enzymatic assays. This approach can aid in the reliable biochemical 
characterization of these enzymes and lead to a better understanding of their substrate 
specificities and biological functions.  
 
Structural Basis for Methylation Site Specificity in JMJD2 KDMs 
 The JMJD2 family of demethylases is an excellent model system to study site specific
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demethylation. Although all members of the JMJD2 family can demethylate H3K9me3 (and the 
closely related repressive mark-H1.4K26me3), only JMJD2A, JMJD2B and JMJD2C can 
efficiently demethylate H3K36me3 whereas JMJD2D lacks specificity for this site. To determine 
the molecular basis of this varied specificity, we determined the crystal structure of JMJD2D in 
the apoenzyme form and in complex with 2-OG and H3K9me3 (Chapter 3). Comparing the 
JMJD2D•H3K9me3 and JMJD2A•H3K9me3 structures, we observed unexpected differences in 
the recognition of H3K9me3 by these enzymes especially at S10 and T11. In addition, we 
showed that the presence of other histone post translational modifications such as T11ph 
abolishes JMJD2 demethylation contrasting previous studies that claimed T11ph enhances 
JMJD2 demethylation during AR signaling [41]. Additionally, docking studies, structural 
comparisons with a JMJD2A•H3K36me3 complex [4] and biochemical analysis with hybrid 
peptides revealed that steric and electrostatic clashes combined with lack of productive 
interactions resulted in the occlusion of H3K36me3 site by JMJD2D. Our structural and 
biochemical data highlights that the determinants of methylation site specificity in the JMJD2 
KDMs are located primarily within the catalytic domain similar to the UTX family which is 
specific for H3K37me3 [8]. This is in stark contrast to other JmjC KDMs such as the PHF8 
family, which require additional domains such the PHD domain for optimal recognition of their 
substrates [7].  It will be interesting to explore the structures of other less understood KDMs such 
as the JARID and JHDM1 families to understand the molecular determinants of their substrate 
specificities.  
 
Separation of H3K9 and H3K36 Site Specificities of JMJD2 KDMs 
 The H3K9me3 and H3K36me3 sites are involved in divergent genomic and biological 
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functions. In humans, the JMJD2 enzymes are the only known family of demethylases that can 
demethylate these methylation marks [3, 9]. Although these enzymes have been structurally and 
biochemically characterized, their biological functions have not been extensively studied. In the 
cases where functional studies have been performed (Table 1.2 from Chapter 1), a vast majority 
of them report different functions for the JMJD2 homologs, implying that these enzymes are not 
functionally redundant. Black et al showed that JMJD2A regulates cell cycle progression by 
demethylating H3K9me3 and increasing chromatin accessibility by antagonizing HP1 
occupancy [42]. Similarly, JMJD2A, JMJD2C and JMJD2D have been shown to upregulate AR 
target genes by demethylating H3K9me3 at target loci such as PSA [29, 32]. JMJD2B has been 
show to play a pivotal role in ER signaling and in the regulation of cyclin-dependent kinases [23, 
28, 31, 33]. More recently, JMJD2D has been shown to regulate cell-type specific gene 
expression in H3K9me3-associated enhancers [43]. Almost all the functions reported for JMJD2 
enzymes pertain to H3K9me3 demethylation whereas their functions associated with H3K36me3 
demethylation remains unexplored. In contrast to H3K9me3 which is associated with 
transcriptional repression and heterochromatin formation [44], H3K36me3 has been implicated 
in regulation of gene splicing and in transcriptional elongation because of its association with the 
elongating form of RNA Polymerase (II) [16, 17, 45, 46]. In addition, H3K36me3 has been 
shown to prevent aberrant transcriptional initiation within coding sequences by recruiting the 
reduced potassium dependency 3 small (Rpd3S) deacetylase complex [46-49]. Since H3K9me3 
and H3K36me3 marks are associated with different functions, demethylation of these marks 
could be associated with non-overlapping functions. In contrast, it is also conceivable that dual-
specificity enzymes like the JMJD2 KDMs could participate in genomic processes that rely on its 
ability to demethylate both H3K9me3 and H3K36me3. To delineate the functions of JMJD2 
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enzymes that rely on H3K9me3 demethylation or H3K36me3 demethylation or both, it would be 
useful to engineer mutations that perturb the specificities in a site specific manner. Using our 
studies on H3K9me3 recognition and H3K36me3 discrimination by JMJD2D, we designed a 
series of mutations in JMJD2A that would make the enzyme either H3K9me3 specific or 
H3K36me3 specific (for a list of mutations and rationale, see Table 5.1). Of the mutations listed, 
we tested the activity of JMJD2A_I71L mutation toward both H3K9me3 and H3K36me3. This 
mutation was based on our docking studies with JMJD2D and H3K36me3, where we showed 
that Leu75 in JMJD2D sterically clashes with R40, a residue critical for H3K36me3 recognition 
by JMJD2A. We hypothesized that mutation of the corresponding Ile71 in JMJD2A to Leu75 
would mirror the steric clash observed in JMJD2D and could potentially impair H3K36me3 
recognition by disrupting the salt bridge formed between R40 and Asp135 in JMJD2A (Figure 
4.9 and 4.10 in Chapter 4). Indeed, a JMJD2A_I71L mutation resulted in ~16 fold decrease in 
catalytic efficiency toward H3K36me3 compared to the WT enzyme (Figure 4.11 and Table 4.4 
in Chapter 4). And, as predicted, H3K9me3 recognition by this mutant was essentially unaffected 
(Figure 4.11 and Table 4.4 in Chapter 4). Hence, a JMJD2A_171L mutant would selectively 
perturb H3K36me3 demethylation and could aid in the understanding of JMJD2A functions that 
pertain to demethylation of this site. In a similar manner, mutations in residues involved in the 
recognition of R8 (such as Y175Q) could impair H3K9me3 demethylation by JMJD2A while 
preserving H3K36me3 activity. These mutations can be expanded to in vivo and cell based 
assays to understand the effects of altered specificity on biological functions. We predict that a 
number of these mutations listed in Table 5.1 will be applicable to other JMJD2 enzymes (due to 
highly conserve nature of these residues) and these studies will furnish a better understanding of 









Table 5.1: Mutations in JMJD2A that can potentially enable separation of specificity 
 







Introduces steric clash at R40 
of H3K36me3 (Figure 4.9 




clashes at residues C-
terminal to H3K36me3 
(Figure 4.12 from Chapter 4) 
 H3K9me3  
I71L; N86H; I87K;Q88K 
Introduces steric and 
electrostatic clashes at 
residues C-terminal to 
H3K36me3 (Figure 4.9 and 
4.12 from Chapter 4) 
 H3K9me3  
Y175Q 
Disrupts hydrogen bonding 
at R8 of H3K9me3 (Figure 
4.1 from Chapter 4) 
 H3K36me3  
E169R; N137E 
Disrupts hydrogen bonding 
and introduces electrostatic 
clash with R8 of H3K9me3 
(Figure 4.1 from Chapter 4) 
 H3K36me3  
E169Q; N137D 
Disrupts hydrogen bonding 
at R8 of H3K9me3 (Figure 




Implications of This Study in Drug Design and Therapy 
 Aberrant expression of specific JMJD2 homologs contributes to the onset or progression 
of breast, prostate, colon, gastric and squamous cell cancers, rendering these enzymes attractive 
targets for chemotherapeutic drug design [18-24, 26-33]. In addition, JMJD2A has been shown 
to upregulate the expression of four-and-a-half LIM domains 1 (FHL1), and promote cardiac 
hypertrophy [34]. A number of research groups have focused on the development of JMJD2 
specific inhibitors to not only probe these enzymes in vivo but also use these compounds as lead 
molecules in drug design [50-55]. As mentioned above, a number of JMJD2 cellular functions 
are non-redundant and there is an impetus on developing inhibitors selective for specific JMJD2 
homologs. Many groups have initiated the development of peptido-mimetic inhibitors based on 
the crystal structures of JMJD2A in complex with H3K9me3 and H3K36me3 [51, 55]. Woon et 
al designed a bi-substrate analog that spans both the 2-OG and peptide binding clefts of 
JMJD2A. These inhibitors were potent for the JMJD2 family with IC50 values of 1.5 µM for 
JMJD2A and 91.0 µM for JMJD2E and exhibited very low affinity (IC50 >1000 µM) for the FIH 
or PHF8 family of enzymes [55]. But these inhibitors displayed some cross-reactivity with other 
KDM families such as JMJD1A and FBX11 with IC50 values ranging from 50.0-60.0 µM. Luo 
et al fused a 2-OG analog with a trimethyllysine mimic and the resultant compound was called 
‘Methylstat’. This cell permeable compound exhibited much broader specificity in inhibiting the 
JMJD2 and UTX families with IC50 values in the range of 5.0-10.0 µM [51]. The major caveats 
with the bi-substrate analogs reported by Woon et al and Luo et al are their lack of specificity for 
specific JMJD2 homologs. Our structural studies revealed that the mutation of T11 to a serine 
increased JMJD2 recognition by 6-10 fold compared to WT H3K9me3 substrate (Figure 4.4 
from Chapter 4),  suggesting that the incorporation of serine-like moieties in these peptido-
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mimetic inhibitors could substantially improve inhibitor affinity. Moreover, certain structural 
differences within the JMJD2 family-such as the GEAR motif in JMJD2D versus the RKDM 
motif in JMJD2A (Figure 4.13 from Chapter 4) could be exploited in the design of inhibitor 
scaffolds that interact with these specific regions thereby achieving high selectivity for specific 
JMJD2 homologs.   
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METHYLATION STATE SPECIFICITY STUDIES USING  
JMJD2A AND JMJD2D 
 
In addition to displaying striking variations in site specificities, the JMJD2 enzymes are 
also an ideal model system to study methylation state specificities. JMJD2A, JMJD2B and 
JMJD2C can demethylate trimethylated lysines and exhibit weak activity for dimethylated 
lysines [1]. JMJD2D on the other hand is highly efficient in demethylating both tri and 
dimethylated lysine. Similar to methylation sites, different methylation states can also signal for 
diverse genomic functions. A genome wide high resolution ChIP-seq analysis revealed that 
H3K9me3 and H3K9me2 are highly prevalent in heterochromatin regions while H3K9me1 was 
reported to be abundant in active promoters near the Transcription Start Sites (TSS) [2]. In 
addition, H3K9 monomethylation is prevalent in the cytosolic histones [3] and its subsequent 
methylation to H3K9me3 in the nucleus is vital for the formation of heterochromatin [4]. The 
mechanisms of state specific demethylation by JMJD2 KDMs have not been studied in detail. 
Using JMJD2A and JMJD2D, we performed structure-function analysis on active site residues 
(JMJD2A_Ser288 and JMJD2D_Ala292) to understand the molecular basis of state specific 
demethylation and explore the role of the unconventional carbon–oxygen (CH•••O) hydrogen 
bonds formed by JMJD2A_Tyr177 in substrate recognition and catalysis. Our studies provide a 
fundamental understanding of how JMJD2 KDMs achieve methylation state specificity and these 
mechanisms most likely hold true for other families of JmjC KDMs.  
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MATERIALS AND METHODS 
Cloning, Expression and Purification of JMJD2A and JMJD2D Mutants 
Mutations in JMJD2A Ser288 and JMJD2D Ala292 were made using the Quikchange 
Mutagenensis method (Stratagene) [Primer sequences are listed in Table A.1]. The mutations 
were verified by DNA sequencing and the Strep(II) tagged JMJD2A and JMJD2D mutants were 
purified as described in Chapter 2.  
 
Incorporation of para-aminophenylalanine (pAF) in JMJD2A 
 The unnatural amino acid pAF was incorporated in JMJD2A using a modified version of 
the protocol reported by Hammill et al [5]. This method is based on the amber stop codon (TAG) 
encoded genetic incorporation of pAF. BL-21 AI cells (Invitrogen) were double transformed 
with 1.5µl each of two plasmids- the first was a plasmid encoding Strep(II) tagged (or his tagged 
for crystallography) JMJD2A in which the codon for Tyr177 was mutated to an amber stop 
codon by Quikchange mutagenesis (see Table A.1 for primer sequences); the second plasmid 
was a pDule2-pAF vector that encodes the tRNA synthetase for pAF incorporation [5].  The 
double transformation reaction was plated on Ampicillin (for the Strep(II) vector) and 
Spectinomycin (for the pDule2-pAF vector) agar plates. After 24 h, the double transformants 
were grown in 150ml of 2XYT media supplemented with 0.1% glucose, 100 µg/ml Ampicillin 
and 100 µg/ml spectinomycin. When the OD of the starter culture was ~1, 10 ml was transferred 
to 500 ml 2XYT media supplemented with the same reagents as mentioned above and the cells 
were grown at 37ºC until the OD reached 0.3-0.4. Subsequently, the temperature was reduced to 
18ºC. After 30 min (when the temperature of the shaker was ~ 20ºC), Arabinose and IPTG were 















Table A.1: Primer sequences for Site-Directed Mutagenesis of JMJD2A and JMJD2D 
MUTANT 
a








Listed in the table is the forward primer. The reverse complement of these sequences were used 




addition of IPTG and arabinose, 1 mM (final concentration) pAF was added to the media (pAF 
was dissolved freshly in autoclaved water and used immediately in the culture). Protein 
expression was allowed to continue for ~48 h (Figure A.1). Cells were centrifuged and the 
pellets were suspended in 100 mM Tris (pH 7.5) and 500 mM NaCl and stored at -20ºC. Strep-
Tactin affinity purification (for enzyme assays) or Ni(II) affinity purification (for 
crystallography) was performed as described in Chapters 2 and 3 respectively. The protein 
expression levels and hence the yield were much lower in the His-tagged JMJD2A Y177pAF and 
protein samples from multiple purifications (at least 3) were used for setting up crystallization 
trials.  
 
Crystallization and Structure Determination of JMJD2A_Y177pAF 
 Crystallization trails were performed as described in Chapter 3. The crystallization mix 
was prepared with 7 mg/ml protein and 1 mM 2-OG. Initial hits were obtained in the PEGs I 
screen (Qiagen) where a number of conditions containing different salts and PEG 3350 produced 
crystals. Rod-clusters from the condition 0.2M sodium fluoride and 20% PEG 3350 were 
crushed in the 96 well plate and used directly for streak seeding using the hanging drop method. 
Seeding into the condition 0.3M sodium fluoride and 14% PEG 3350 resulted in the formation of 
rod clusters and a few individual rods (Figure A.2). These crystals were harvested by serial 
transfer into the crystallization solution supplemented with 5%, 15% and 25% 1,2-propanediol 
and subsequently flash frozen in liquid nitrogen. Diffraction data were collected at the Life 
Sciences-Collaborative Access Team (LS-CAT) beamline 21-ID-G at the Advanced Photon 
Source Synchrotron (Argonne, IL). The JMJD2A_Y177pAF crystals diffracted to 3.2 Å and the 











Figure A.1; Expression analysis of JMJD2A_Y177pAF. Lane 1: Molecular weight standards; 
Lane 2: Strep(II) tagged JMJD2A (WT); Lane 3: Uninduced culture; Lane 4: Culture induced 
with IPTG; Lane 5: Culture induced with IPTG and pAF for 48 h. Black and red arrows indicate 



























Figure A.2: Crystals of JMJD2A_Y177pAF obtained by streak seeding. These crystals were 







Table A.2: Crystallographic Data and Refinement Statistics of JMJD2A_Y177pAF 
 
  JMJD2A_Y177pAF 
Data Collection   
Beamline  APS 21-ID-G 
Wavelength (Å)  0.9786 
Space Group  P21212 
Cell Dimensions a,b,c (Å)  101.0, 148.9, 57.34 
Resolution Range (Å)a  83.6-3.25 (3.36-3.25) 
I/I a  20.7 (6.87) 
Completeness (%)a  99.75 (97.77) 
Refinement & Validationb   
No. of Reflections  13,469 
No. of Atoms  5392 
Protein Atoms  5344 
Ligand Atoms  4 
Solvent Atoms  44 
Rwork/Rfree
 c  0.20/ 0.30 
B-factors (Å2)   
Overall  45.3 
Protein  45.4 
Ligands  34.0 
Waters  30.0 
Root mean square deviation   
Bond Length (Å)  0.012 
Bond Angles (°)  1.36 
MolProbity Scores   
Clashscore (all atoms)d  16.12 (97th percentile N=37) 
Molprobity Score  2.7 (94th percentile N=1581) 
Resolution Range (Å)  3.25 ± 0.25 
Ramachandran   
Favored (%)  94.4 
Allowed  (%)  5.2 




a Values in parentheses correspond to the highest-resolution shell. b Structures were refined in Refmac [6] using overall 
temperature-factor refinement  c Rwork = Σ ||Fo|-|Fc|| / Σ |Fo| ; Rfree = 5% of the total reflections.  
d Clashscore is the number of 




crystallization, there was no discernible electron density for 2-OG in our structure. Data was 
processed and scaled using HKL2000 [7]. Molecular replacement was performed using 
MOLREP [8] with a JMJD2A structure (PDB entry: 2Q8C) used as the search model. Model 
building and refinement were conducted using Coot and Refmac, respectively [6, 9]. There was 
significant deviation between the Rwork and Rfree values (Table A.2) potentially due to the poor 
data quality and model bias. Refinement was done using overall B factors. After refinement, 
structures were validated using MOLPROBITY [10]. Structural figures were rendered using 
PyMOL (Schrödinger, LLC). 
 
Histone Substrate Peptides and FDH-Coupled Demethylase Assay 
 Tri-, di- and monomethylated histone H3 peptide substrates used in the kinetic analyses 
of JMJD2A and JMJD2D and the various mutants were purchased from Anaspec Inc., and were 
purified with a chloride counter ion. Peptide concentrations were quantified by amino acid 




Active Site Residues Determine Methylation State Specificity 
 The active sites of JMJD2A and JMJD2D are highly conserved with the exception of a 
single amino acid difference. In JMJD2A, the side chain hydroxyl of Ser288 in the active site 
forms critical CH•••O hydrogen bonds to the substrate methyl groups (Figure A.3). These set of 
interactions are absent in JMJD2D where Ser288 is substituted by Ala292. This single amino 














Figure A.3: Comparison of the active sites of JMJD2D and JMJD2A. Active site structures 
of (A) JMJD2D (pink) bound to 2-OG (black) and K9me3 in histone H3 (green) and (B) 
JMJD2A (blue) in complex with 2-OG and K9me3 (yellow). CH•••O hydrogen bonding between 
the K9me3 methyl groups and active site atoms are represented by dark blue dashed lines. Co-







enzymes. It was shown by Couture et al., that an S288A mutation in JMJD2A imparted the 
enzyme with activity toward dimethyllysines but a A292S mutation in JMJD2D had lower 
catalytic activity for both tri and dimethyllysines [11]. These analyses were performed using 
Ni(II) column purified enzymes and reported very low turnover numbers. We performed kinetic 
analysis on Strep-Tactin column purified JMJD2A_S288A and JMJD2D_A292S mutants. We 
observed a similar change in substrate specificity in JMJD2A albeit with much higher turnover 
numbers (Figure A.4 and Table A.3). The JMJD2A_S288A mutant displayed a 10-fold increase 
in catalytic efficiency for H3K9me2 compared to WT JMJD2A. Similar to previous reports by  
Couture et al [11], a JMJD2D_A292S mutant had a 10-fold decrease in catalytic efficiency 
toward both H3K9me2 and H3K9me3. Interestingly however, for H3K9me2, the kcat was 
reduced 10-fold while for H3K9me3, the Km was increased by 10-fold. These results show that 
the active site Ala292 in JMJD2D might play different roles in the demethylation of H3K9me2 
and H3K9me3. When we tested the activity of the JMJD2A_S288A and JMJD2D_A292S 
mutants and the WT enzymes for H3K9me1, we were unable to detect any measurable activity 
corroborating previous studies that the JMJD2 enzymes do not display activity toward 
monomethyllysines [1, 11]. To test the effects of other substitutions at JMJD2A Ser288, we 
mutated it to Cys, Thr and Val. Even though the mutants were stable after purification, they 
lacked catalytic activity toward all three methylation states suggesting that these residues 
sterically occlude the binding of methylated substrates (data not shown).  
 
JMJD2A_Y177pAF is Catalytically Inactive 
 In addition to Ser288, Tyr177 also forms CH•••O hydrogen bonds with the substrate 











Figure A.4: Activity of JMJD2A, JMJD2D and their state specificity mutants. The kinetic 













Table A.3: Kinetic analysis of JMJD2A, JMJD2D, JMJD2A_S288A and JMJD2D_A292S 
with H3K9me2 and H3K9me3 
 
 













JMJD2A_WT 0.29 ± 0.01 110 ± 11 2.7 ± 0.3 
JMJD2A_S288A 1.3 ± 0.1 83 ± 1 15 ± 1 
JMJD2D_WT 1.0 ± 0.1 31 ± 5 34 ±  5 
JMJD2D_A292S 0.10 ± 0.01 28 ± 3 3.7 ± 0.6 
H3K9me3 kinetics 
JMJD2A_WT 1.7 ± 0.1 56 ± 9 31 ± 4 
JMJD2A_S288A 1.3 ± 0.1 37 ± 3 36 ± 1 
JMJD2D_WT 2.3 ± 0.2 53 ± 9 45 ± 4 
JMJD2D_A292S 1.3 ± 0.1 200 ± 7 6.3 ± 0.2 
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residue, we mutated Tyr177 to the unnatural amino acid, para-aminophenylalanine (pAF). A 
phenylalanine mutation at Tyr177 could potentially disrupt critical structural hydrogen bonds in 
addition to the active site CH•••O bonds. A pAF mutation however, would preserve the structural 
hydrogen bonds and hence enabled us to selectively perturb only the active site CH•••O 
hydrogen bonds. Our kinetic analyses of JMJD2A_Y177pAF mutant revealed that the enzyme 
was inactive toward H3K9me3, H3K9me2 and H3K9me1 suggesting that  CH•••O bonds formed 
by Tyr177 are pivotal for catalysis. We also determined a 3.2 Å crystal structure of 
JMJD2A_Y177pAF with Ni(II) in the active site to verify that the protein was folded and the 
pAF substitution did not alter the structure. The mutation of Y177 to pAF resulted in no major 
structural deviations compared to WT JMJD2A (RMSD Cα= 0.32Å) (Figure A.5).  
 
DISCUSSION 
In contrast to methylation site specificity which is determined by residues distal to the 
active site, our studies reveal that the active site residues largely determine methylation state 
specificity of JMJD2 lysine demethylases. In particular, the active site Ser288 in JMJD2A and 
Ala292 in JMJD2D are the state specificity determinants which dictate the preference of 
different methylation states for these enzymes. Although the biochemical effects of these 
mutants has been explored, studying the effects of varied state specificities, in particular, the 
JMJD2A_S288A mutant in vivo would be instrumental in understanding the biological 
significance of state specific demethylation by JMJD2 KDMs.  
 Our studies on the JMJD2A_Y177pAF revealed that the CH•••O hydrogen bonds formed 
at this position are indispensable for catalysis. To our knowledge this is the first time, an 













Figure A.5: Alignment of the JMJD2A_WT and JMJD2A_Y177pAF structures. 
Incorporation of the unnatural amino acid pAF at position 177 did not result in major structural 





structurally characterized. These studies open the platform for the use of unnatural amino acids 
as viable tools to understanding the biochemical and physiological functions of these enzymes.     
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